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CHAPTER I
STATEMENT OF THE PROBLEM
Female life expectancy in the United States has steadily increased and
now averages 81 years, meanwhile the age at which women reach
menopause remains constant at 51 years. Therefore, women live over one
third of their life in a post-menopausal, low estrogenic state. Both neurological
and cardiovascular disorders increase following menopause, affecting
women’s quality of life and leading to large health care costs.
Various epidemiological and basic science studies show that estrogen
administration (Estrogen Therapy (ET)) can have neuroprotective effects and
improve cognitive abilities in aging women, as well as reduce heart disease
and overall mortality. The Women’s Health Initiative (WHI), a large clinical
study conducted in menopausal women, had contradicting conclusions but
established that age is an important factor in determining positive or negative
outcome of ET. This led to the formulation of the “Timing Hypothesis”:
exposure to estrogens is beneficial for younger women but has detrimental
outcomes in post-menopausal women who have experienced an extensive
hypo-estrogenic period. While its underlying mechanisms are unclear, it is
well accepted that the female brain and heart respond differently to ET before
and after menopause, indicating that cellular and molecular components in
these tissues undergo some kind of modification during the perimenopausal
transition.

The effects of estrogen are mediated by two high affinity nuclear
receptors, Estrogen Receptor α (ERα) and Estrogen Receptor β (ERβ) and
the G-protein coupled estrogen receptor1 (GPER) . Evidence supports that
ERβ plays an important role in neuroprotection and cardioprotection, but
aspects of ERβ molecular signaling are still not fully understood. One
possibility is that aging and estrogen deprivation alter ERβ post translational
modifications, such as phosphorylation. Indeed the mitogen activated protein
kinases (MAPKs) responsible for phosphorylation of ERβ have been shown to
be modulated by aging and steroid hormones. The goal of my dissertation is
to determine the consequences of ERβ phosphorylation and how prolonged
estrogen deprivation prior to estrogen treatment alters MAPKs signaling in the
brain and heart.
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CHAPTER II
LITERATURE REVIEW
ESTROGEN SYNTHESIS AND MENOPAUSE

Estrogens are the primary female sex hormones; they are mostly
produced by the ovaries, corpus luteum and placenta in premenopausal
women [1]. A smaller amount of estrogens is also produced by non gonadal
organs such as the brain, liver, heart and skin. The three major forms of
estrogens in women are estrone (E1), 17β-estradiol (E2) and estriol (E3). The
most potent and prevalent estrogen in premenopausal women is E2, which is
produced within the ovary by thecal and granulosa cells. Aromatase is the
enzyme necessary for the final step of E2 synthesis, and it is expressed in
granulosa cells as well as in peripheral organs. During the menstrual cycle,
E2 is highest right before ovulation, reaching 110-410 pg/ml. In
perimenopause E2 levels fluctuate and then decrease to below 35 pg/ml in
postmenopausal women [1, 2]. The average age at menopause is 48-52 in
developed countries and reflects the exhaustion of functional follicles in the
ovaries. The number of follicular oocytes is set before birth and declines with
apoptotic events before and after puberty. When women reach 45-55 years of
age the oocytes are exhausted leading to a cascade of events ending with
neuroendocrine desynchronization, fluctuations in estrogens levels and
ultimately menopause [2].

Following menopause, estrone is the prevalent circulating estrogen;
estrone is synthetized from conversion of androstenedione in adipose tissue,
neurons and astrocytes [3]. Analyses of post-menopausal women who
underwent natural menopause determined that adipose tissue mass
correlates with estrone levels, which had osteoprotective effects and
increased bone mineral density as well as decreased colorectal cancer risk [4]
[5]. However, high estrone levels in post menopausal women also have been
found to correlate with increased ER-positive breast cancer [6]. Estrone has
higher affinity for ERα than ERβ, however it was shown to induce coregulatory
protein recruitment to ERβ more efficiently than ERα [7, 8]. The third
physiological estrogen, estriol, is the weakest activator of ERs and is
produced during pregnancy by the fetal liver and adrenal glands [9].
Interestingly, estriol has been found to decrease the symptoms of multiple
sclerosis (MS), explaining the improvement of women with MS during
pregnancy [10].
NEUROPROTECTION OF ESTROGEN
Learning and Memory
The study of the effects of estrogens on cognitive functions started in
the 1950’s when a random controlled study on 75-year old women showed
that 12 months of treatment with E2 improved their verbal intelligence quotient
(IQ) while the IQ scores of the placebo treated women decreased over that
same period of time [11]. Since then randomized observational and
longitudinal studies have investigated the clinical effects of estrogens on
cognitive functions, anxiety, mood, and memory using standard tests of
neuropsychological function. Overall 71% of studies concluded a significant
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beneficial effects of E2 [12]. However interpretation of these studies is
complicated by several confounding variables such as age and dosage, tests
used to evaluate cognition, and length of treatment. A more definitive
understanding of the molecular effects of E2 is needed to help physicians
better treat their patients.
Basic science studies have elucidated some of the mechanisms behind
the neuroprotective effects of estrogens. In the 1990s, Catherine Woolley and
Bruce McEwen found that E2 levels fluctuating across the estrous cycle
correlate with synaptic changes in the hippocampus of female rats [13, 14].
Indeed, higher E2 levels coincided with increased synaptic density, increased
dendritic spines and arborization. In an in vivo study using ERβ-null mice, Liu
showed that ERβ is required for the E2-enhanced hippocampal synaptic
plasticity and hippocampal dependent cognition [15]. These and other studies
have therefore linked E2 to synaptic plasticity changes in neuronal circuitry
and architecture [16]. Moreover, behavioral experiments using female rats
show that changes in their learning strategy vary with natural hormonal
fluctuations, such as during the estrous cycle, strongly implying that
hippocampal mediated learning and cognition was intrinsically linked with
circulating levels of estrogens [17]. In an extensive behavioral analysis, Kiss
et al. evaluated the effects of E2 treatment on cognition and depressive-like
behaviors in young (3 mo), adult (7 mo) and middle-aged (12 mo) female rats
[18]. Their results showed that E2 treatment improved spatial reference
memory in all age groups and was beneficial for depressive-like behaviors in
young and middle-aged rats. Correlating with the behavioral data with
neurochemical evaluations, hippocampal brain-derived neurotrophic factor
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(BDNF) levels were increased by E2 treatment at all time points, while
decreasing with age. BDNF mediates neuronal growth, survival, and plasticity
in the nervous system. Several lines of evidence support an interaction
between E2 and BDNF and their downstream neuroprotective, neurotrophic,
and neuromodulatory effects [19]. Estrogens and BDNF have similar effects
on the hippocampus and in the past years many studies have focused on the
idea that BDNF is a mediator of estrogens’ effects. [20, 21]. By comparing the
immunoreactivity of BDNF in the hippocampus during the estrous cycle,
Sharfman showed that BDNF levels also cycle according to cycling estrogens
[22].
Pathogenic conditions
Interestingly, studies suggest that E2 might prevent or delay the onset
of Alzheimer’s disease (AD), the most common cause of dementia in women.
In a 1998 meta-analysis Yaffe et al. concluded that treatment with estrogens
decreased the risk of developing dementia in postmenopausal women by 29%
and that several plausible biological mechanisms exist that could support
estrogens’ use as a preventative and beneficial treatment of AD [23]. Casecontrolled clinical studies have been conducted since then, and a 2001 metaanalysis concluded there is a 34% decreased risk of Alzheimer disease in
women taking hormone treatment [24]. Research using animal models has
also investigated a putative link between AD and E2 therapy. For instance, a
recent study evaluated the use of a nonsteroidal selective androgen receptor
agonist together with an ERβ agonist in a mouse model of AD, which resulted
in improved cognition, reduced anxiety behaviors as well as an increase in
Amyloid-β degrading enzymes [25]. The authors speculate that ERβ agonists
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could be used as a potential therapy of patients with AD by interfering with the
progression of the disease through degrading and clearing Amyloid β. In
transgenic models of AD, different ERβ agonists led to prolonged survival,
improved spatial recognition memory, cognition and lowered Amyloid-β
accumulation [25, 26]. In the case of Parkinson’s disease (PD) and other
neurodegenerative diseases, estrogens have been shown to protect the
nigrostriatal dopaminergic pathway that is affected by these diseases [27, 28].
It is thought that both ERα and ERβ are necessary for this protection;
however an animal model of PD showed that treatment with the ERβ agonist
AC-186 prevented motor and cognitive deficits and mitigated neuronal loss in
males but not in females [29, 30].
Other neuroprotective effects of estrogens have been attributed to
ERβ. For example, several ERβ selective agonists have been shown to
induce remyelination and repair in animal models of multiple sclerosis [31].
Inflammatory and neuropathic pains are also targets of ERβ regulation, as
shown in vivo using the ERβ selective agent ERb-131 [32, 33]. Gliomas,
aggressive brain tumors, are more common in males than females, indicating
a possible beneficial effect of the higher levels of circulating estrogens in
females; interestingly ERβ is highly expressed in male and female glioma
cells, while ERα is not detected [34]. Indeed treatment with ERβ agonists
DPN (Diarylpropionitrile) or liquitrigenin reduced proliferation in an in vitro
glioma model and in vivo in mice that had a glioma xenograft [34].
Estrogens have also been shown to be neuroprotective in models of
cerebral ischemia. Women overall have a lower incidence of stroke than men,
but following menopause this difference decreases [35]. Studies have proven
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that E2 exerts dramatic protection if administered either before or after the
ischemic injury [36, 37]. For example, E2 treatment for seven days
significantly reduced infarct size in a middle cerebral artery occlusion (MCAO)
ischemic injury paradigm [37]. Moreover, a 2013 study showed periodic E2
treatment increased neuronal survival following cerebral ischemia via bilateral
carotid occlusion and systemic hypotension. [38] The study also
demonstrated that learning and memory following ischemic damage was
improved when the rats where administered an ERβ specific agonist, which
might have been mediated by the ERβ dependent increase in CREB
phosphorylation.
Mood and affective disorders
The role of estrogen in anxiety and depressive disorders has been
investigated both in clinical and basic science fields. Women experience
increased depression, sleep disturbances, irritability, anxiety and panic
disorders after menopause and ET has been show to improve mood, feelings
of wellbeing and an overall increase in activity [39]. However, women in
general report higher incidence of depression than men, yet animal models
have shown both anxiogenic and anxiolytic actions of E2. These discrepant
findings can be partly explained by differential actions mediated by the two
estrogen receptor isoforms, ERα and ERβ. For instance, a 2005 paper by
Lund et al., demonstrated that treatment with an ERβ specific agonist
decreased anxiety-related behaviors in rats, whereas ERα specific agonists
were anxiogenic [39]. Their findings suggest that the conflicting effects of
estrogens might be due to inverse actions on anxiety behaviors by the two
ERs. Indeed, studies have shown that ERα and ERβ have different signaling
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pathways and downstream gene targets despite their equivalent binding
affinity for E2 [40]. Overall, ERβ has beneficial effects on neurological
diseases that have very different etiologies and in which different cell types
are involved, highlighting its multifaceted functions.
CARDIOPROTECTION OF ESTROGEN
The sex difference in the incidence of cardiovascular disease is well
documented, women are less likely to develop heart disease than men, but
this advantage is lost after menopause presumably due to significant
reduction in circulating E2 [41-43].
Both estrogen receptor isoforms, ERα and ERβ, are widely expressed
in cardiovascular tissue, in cardiac myocytes, fibroblasts, vascular smooth
muscle cells and endothelial cells and can influence gene expression as well
as have rapid non genomic effects [44]. ERβ deficient mice develop
hypertension, vascular dysfunction, and abnormal heart morphology as they
age and therefore have been used to reveal the role for this receptor isoform
in mediating E2 effects in the cardiovascular system. A study from Dr. E.
Murphy found that ERβ mediates functional recovery following
ischemia/reperfusion injury possibly by its regulation of fatty acid metabolism
genes important in ischemic injury [45].
The development of several SERMs (selective estrogen-receptor
modulators) also contributed to the understanding of the importance of ERβ in
the cardiovascular system. ERβ-specific agonists reduced arterial pressure in
ovariectomized spontaneously hypertensive rats, increased cardiac output
and left ventricular stroke volume [46]. The same study also showed that ERβ
activation also improved vascular reactivity and increased ERβ expression in
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the aortic ring, both in endothelial cells in the intima and vascular smooth
muscle cells [46]. Overall the study showed that ERβ specific agonists
attenuate hypertension, vascular resistance and cardiac hypertrophy in
spontaneously hypertensive rats. The authors also speculated that these
positive effects might be mediated by enhanced vascular Nitric Oxide (NO)
generation both via genomic and non-genomic mechanisms. Indeed ER
increases expression of enzymes responsible for NO synthesis as well as
activating them, possibly by recruiting and activating kinases [47].
ERβ is necessary for the observed gendered differences in the
attenuation of the hypertrophic response to pressure overload and improved
recovery from ischemia/reperfusion injury [48, 49]. Furthermore, in animal
models of ischemia reperfusion injury, treatment with the ERβ specific agonist
improves functional recovery and upregulates protective genes such as
antiapoptotic proteins, heat shock proteins and cyclooxygenase 2 [50]. These
and other studies led to the proposal by Kathryn Sandber and Hong Ji that
ERβ could be the “Alpha-Dog” in estrogen receptor-mediated protection from
hypertension [51].
An additional factor to consider when studying the effects of estrogen
in post menopause is the comorbidity of depression and cardiovascular
disease (CD) which ranges from 20 to 40% according to different studies.
Middle-aged women are particularly susceptible to higher mortality following
myocardial infarction (MI) if they have depressive symptoms (50% greater
risk) [52-54]. The interesting link between heart disease and depression was
analyzed in the SADHART trial (Sertraline AntiDepressant Heart Attack Trial),
which was aimed at evaluating the effectiveness of the selective serotonin
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reuptake inhibitor (SSRI) Sertraline in treating major depression in patients
with acute myocardial infarction (MI) or unstable angina. The trial concluded
that Sertaline is safe and efficacious in depressed patients with ischemic heart
disease, but could not detect differences in mortality between placebo and
Sertaline treated patients because it was underpowered. It is also difficult to
determine whether depression is a risk factor for coronary heart disease
(CHD) or a cause of it. Kenneth E Freeland and Robert M Carney in a recent
report supported the idea that depression predicts worse outcome in patients
with CHD and possibly improving the depressive symptoms could determine
better cardiovascular prognosis [55]. Not only is comorbidity of depression
and CD increasingly prevalent in middle-aged patients, but also menopausal
women are particularly susceptible to have both these conditions. The
elevated risk of both depression and CD in menopausal women is well
accepted but the reason for this or the possible improvement from using HT
needs further investigation [53].
Overall, several studies confirm estrogen’s positive effects on the
cardiovascular system and the importance of ERβ in mediating these
responses, but how age and timing of ET influences cardioprotection needs
further investigation.
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Positive effects of ERβ
Neuroprotection

Cardioprotection

Improve neuronal survival

Reduce ventricular hypertrophy

Induce remyelination in MS

Reduce ischemia/reperfusion
injury

Prevent motor and cognitive
deficits in PD

Induce vasodilation
Reduce atherosclerosis

Reduce
Neuropathic/inflammatory Pain

Reduce coronary heart disease

Reduce glioma size
Improve memory

Delay/prevent dementia and
AD

Figure 1 Summary of studies depicting the specific cardioprotective and
neuroprotective effects of ERβ.
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THE TIMING HYPOTHESIS
The constant theme in neuroprotection and cardioprotection of
estrogens in clinical studies is the importance of the time of initiation of ET
(estrogen therapy alone) in women. The concepts referred to as “window of
opportunity” or “timing hypothesis” emerged when analyzing several clinical
studies and finding that the variety of results was due to the span of ages of
the women enrolled in the studies. When analyzing data by grouping for the
age of initiation of ET, it was clear that estrogens alone reduced risk of
cognitive decline and dementia when administered to women in the early
stage of menopause [56]. Postmenopausal women receiving ET in a 2012
Danish study also had significantly reduced risk of mortality and heart failure,
without an increased risk of breast cancer or stroke [57]. The WHI ET followup showed that women 50-59 of age had statistically significant reduction in
coronary heart disease (Hazard Ratio (HR) of 0.59), myocardial infarction (HR
0.54) and overall mortality (0.73) [58]. These are only a few examples of how
cognitive and cardiovascular health of menopausal women can be improved if
ET is started at the right time (i.e. in early menopause).
Despite the well-established evidence for cardioprotective effects of
E2, the large scale clinical trial designed to assess the health benefits of E2 in
postmenopausal women – the WHI- was suspended because of an increased
risk of stroke and coronary heart disease among the HT participants [59].
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The Timing Hypothesis

Death

AD
Coronary heart
Disease

Hazard ratio

Dementia

50-59

60-69

70-79

Age of ET
initiation

Atherosclerosis
Fractures

Figure 2. The Timing Hypothesis.

Unfortunately, most physicians stopped prescribing ET to their patients
after the WHI prematurely interrupted its study in 2002 and published their
early results that showed adverse effects and increased mortality. A recent
analysis by Dr. Phillip Sarrel published in the American Journal of Public
health made the news when the author stated that avoiding ET by women in
2002-2011 caused the premature death of 50000 women [60]. He then
emphasized the need to call attention to the beneficial effects of ET for
women 50-59 which should prompt doctors to prescribe it to their patients in
that age group. A better understanding of the contribution of age on the
effects of estrogen on cognitive and cardiovascular health are needed to help
guide physicians in providing the best care to their patients, and my project
will shed light on the molecular mechanisms for this age-related shift in E2
efficacy.
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ESTROGEN RECEPTOR BETA
Estrogen receptors are nuclear steroid receptors widely expressed in
both reproductive and non-reproductive tissues and act as transcription
factors; therefore they play a central role in many life processes including
normal physiology [61]. In 1996 a group led by Jan-Ake Gustavsson
successfully cloned the second estrogen receptor, expressed in rat prostate
and ovary, named ERβ [62]. Initially described as a 485 amino acid long
protein, further studies revealed an upstream AUG start site, making rERβ
530 amino acids long, with a calculated molecular weight (MW) of 59.152 KDa
[63]. Subsequent studies identified several splice variants, the first and better
characterized being ERβ2, first described in 1998 and widely expressed [64].
In the brain ERβ is expressed in several hypothalamic nuclei, hippocampus,
cerebellum, olfactory bulb, amygdala, cortex, and spinal cord [65].
Peripherally it is expressed in the cardiovascular system (myocytes,
endothelial cells, fibrocytes), ovary, prostate, skeletal system (osteoblasts,
osteoclasts and osteocytes), gastrointestinal tract, pancreas, adipose tissue
and liver [61].

1

148

AF-1

214

DBD

500

304

AF-2-LBD
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Figure. 3. Domains of ERβ.
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The structure of ERβ is that of a classical nuclear steroid receptor
organized in domains each with a particular structure and specific functions
(Fig.3). The N-terminal A and B domains are collectively defined as AF-1
(Activation Function-1, or N-terminal transactivation domain), a highly variable
domain amongst the steroid receptor family. Many residues in the AF-1
domain are phosphorylated by various kinases; the AF-1 domain is also
fundamental for binding to coregulatory proteins [63, 66]. The AF-1 domain is
intrinsically disordered (ID) in solution, therefore its structure is difficult to
analyze, but progress is being made in understanding its binding to
coregulatory proteins that leads to modulation of its transcriptional regulation
[67]. This domain is also thought to mediate the known ligand independent
regulation of transcription by ERβ [68-70]. The C domain is the DNA-Binding
Domain (DBD) involved in DNA recognition and binding. In the case of
estrogen receptors the DBD recognizes Estrogen Responsive Elements
(EREs), in the promoter of target genes. The DBD is partially conserved with
ERα, which can also recognize and bind to ERE sequences. The ERE is an
inverted palindromic DNA consensus sequence (5’ GGTCAnnnTGACC 3’)
that the DBD has a high affinity for [71]. The D domain of ERβ is the hinge
domain, a flexible domain allowing for the conformational changes of the
receptor. The E domain is the Ligand Binding Domain (LBD) or AF-2, which is
responsible for ligand binding of both agonists and antagonists, dimerization,
interactions with coregulatory proteins and conformational changes caused by
ligand binding [72]. The precise function of the small C-terminal F domain of
ERβ has not been identified yet, although it has been proposed to influence
ligand binding and coactivator binding [73].
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According to the classic model of steroid receptor functioning, ERβ is
normally present in the cytoplasm bound to chaperone proteins. Following
ligand binding it dimerizes and translocates to the nucleus, where it binds to
the ERE and, together with coregulatory proteins, activates gene transcription
(Fig. 4). Steroid receptors are therefore highly dynamic, being shuttled to and
from the nucleus and in proximity of the cell membrane or cellular organelles.

E2

Hsp90

Regulation of
Transcription

E2

Coregulators

E2

E2
RNA Pol

Figure 4. Classical model of ERβ’s action.

17

Transcription
Factors

The ERα and ERβ isoforms can often be co-expressed in a tissue and form
homo or heterodimers. It was shown in 1997 that ERα and β can form
heterodimers on the DNA at ERE sequences and are capable of binding to
coregulatory proteins and activating transcription [74]. However the
heterodimer is potentially functionally distinct from the homodimer, giving ERs
a wider possibility of gene regulation. The characteristics of the heterodimer
were analyzed in vitro in a 2004 paper by Li et al. showing that heterodimer
binding to E2 and activation of ERE were similar to the α-α homodimer [75].
However ERβ is known to act as a dominant inhibitor of ERα, and it was
initially thought that the function of ERβ was to modulate ERα transcriptional
activity [76]. This adds to the complexity of estrogens' signaling and
determines the variety of effects estrogens can have in vivo in different
tissues that display different expression of ERα and ERβ.
PHOSPHORYLATION OF ERβ
Post translational modifications (PTMs) such as phosphorylation,
ubiquitination, acetylation and sumoylation have been identified for several
steroid receptors, including ERs. These modifications can potentially alter
each step of ERs function from ligand binding, dimerization, protein:protein
interactions, DNA binding and ultimately ER function [66, 77]. For example,
the first evidence that ERs can have ligand independent function was
attributed to phosphorylation of the receptor after epidermal growth factor
(EGF) treatment [78]. Furthermore EGF treatment to ovariectomized rats
mimicked the effects of estrogens, as it leads to proliferation in the uterus [79]
. We now know that extracellular factors such as EGF can initiate the
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signaling cascade leading to kinase activation and ER phosphorylation and
activation.
Although consensus sites for several kinases are present in ERβ, only
a few have been described and confirmed as actual phosphorylation sites
[66]. The experimentally confirmed phosphorylation sites for the human ERβ
are S87 and S105 [80, 81]. Studies of the phosphorylation of the mouse
isoform of ERβ have also shown phosphorylation at the homologous sites
(S106 and S124) and other sites mostly in the N-terminal domain, which are
less characterized [68].
Phosphorylation of ERβ has important functional implications. In a
2012 paper by Lam et al. phosphorylation of S105 inhibited breast cancer cell
invasion and migration in vitro [81]. Phosphorylated S105 is also highly
prevalent in human samples of breast cancer tissue, where ERβ is known to
be antiproliferative [81, 82]. Phosphorylation of hERβ at S87 and S105
(mouse S106 S124) was shown to recruit the coregulatory protein steroid
receptor coactivator-1 (SRC-1) in vitro and increase transcriptional activation
at ERE in a ligand independent way [68]. The phosphorylation of ERβ has
been shown to be mediated by two MAPKs, p38 and ERK, in in vitro kinase
assays on the human and mouse ERβ form [68, 81].
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Figure 5. ERβ phosphorylation sites.

Overall phosphorylation of steroid receptors is pivotal for their
functioning, and the little that is understood about the actual phosphorylation
of ERβ and how these influence their functioning is mostly from in vitro studies
using breast cancer cell models. More needs to be done to characterize the
molecular functional consequences of phosphorylation and describe ERβ
phosphorylation in non-cancerous tissues, such as the brain and heart where
ERβ is known to have important functions. Furthermore, to my knowledge
there are no reports describing the effects of age and E2 on ERβ
phosphorylation.
COREGULATORY PROTEINS
The recruitment of coregulatory proteins to steroid receptors is a
fundamental step in their functioning. Coregulatory proteins can activate
(coactivators) or repress (corepressors) gene transcription and are required
for proper signaling of all steroid receptors. After binding to the steroid
receptor they serve as scaffolds for the larger complex of proteins that form
the pre-initiation complex on the promoter of the responsive gene. Most of the
classic coregulatory proteins for ER belong to the SRC (Steroid Receptor
Coregulator) family and were first identified in 1994 in the lab of Myles Brown
as estrogen-receptor associated proteins necessary for ER functions [83].
Since then the functions of SRC proteins have been elucidated and their
importance in cell physiology has grown. Coregulatory proteins were recently
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defined by Dr. Bert O’Malley as “masters of system biology” to emphasize
their importance [84]. They are not mere bridges between ERβ and the
transcriptional machinery but integrate signaling cascades by binding to
multiple transcription factors, and their dysregulation can lead to serious
consequences such as development of cancer [85]. The coactivators SRC1
and SRC3 interact and positively regulate transcriptional regulation mediated
by several steroid receptors, including ERβ. Corepressors, such as silencing
mediator for retinoid and thyroid hormone receptor (SMRT) and nuclear
receptor corepressor (NCoR), repress or silence steroid receptor mediated
regulation of transcriptional activity [85].
To date, more than 350 steroid receptor coregulators have been
reported. However the ER interactome comprises an impressive amount of
proteins, not only classic coregulators but binding partners involved with cell
functions ranging from apoptosis to cell structural proteins to metabolic
proteins to RNA splicing. For example, over 743 proteins associate with ERβ
in the ventral hippocampus and several of these interactions are age and
estrogen dependent [86]. Other studies have shown that the interactome of
ERs in breast cancers is made of hundreds of proteins [87, 88]. These newly
discovered interacting partners are an insight to the potentials of ER signaling.
MITOGEN ACTIVATED PROTEIN KINASES
Age and E2 modulate cell signaling pathways critical for regulating
basic cellular processes. Mitogen Activated Protein Kinases (MAPKs) are a
family of Serine-Threonine protein kinases that link extracellular signals to
intracellular responses [89, 90]. They are highly complex and interesting as
they regulate cell activities including proliferation, differentiation, apoptosis
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and cell survival. Nearly every physiological and pathological event studied
involves MAPKs, which indicates not only their essentiality but also their
complexity. The MAPK family includes p38 MAPK, extracellular signalregulated kinase (ERK) and c-Jun NH2-terminal kinase (JNK), however as
only p38 and ERK kinases have been shown to target ERβ for
phosphorylation we will focus our attention to those [68, 81].
MAPK family members were first discovered and sequenced in the
1980s and 90s after their activation was observed following mitogens
stimulation, hence their name [90]. These kinases are regulated themselves
by phosphorylation at their Threonine-x-Tyrosine phosphorylation site motif.
MAPKs activation is the last of a three step activation cascade from MAP3K to
MAP2K to MAPK. Once phosphorylated (i.e. activated) they in turn
phosphorylate substrate proteins at Serine or Threonine residues in specific
recognition sequences [91]. While MAPKs phosphorylate S/T residues
included in a conserved motif, this sequence is variable, allowing for substrate
discrimination and a wider pool of targets [92]. The strongest requirement for
phosphorylation common to p38 and ERK kinases is the presence of a Proline
directly at the C- Terminus of the phosphorylation site. Another characteristic
feature of MAPKs is the presence of docking sites in their substrates; the best
characterized being D-sites and F-sites [93]. These mediate the interaction
between sequence motifs in the target protein far from the phosphorylation
sites and region of the kinase separate from the active site. Because of their
heterogeneous preference for D- and F- sites, ERK and p38 interact with
different target proteins, therefore having differential downstream effects.
Furthermore docking sites assure specificity and selectivity of kinase
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substrate interactions, reducing the number of potential substrates [93].
Interestingly 30% of human proteins have at least one MAPK phosphorylation
site; however fewer have the docking sites necessary for the kinases to
interact strongly and phosphorylate them.
The knowledge of the activators, substrates and functions of MAPKs
are ever expanding, however when they were first discovered they were
deemed stress-activated protein kinases (SAPKs) because of their
responsiveness to toxins, physical stresses and inflammatory cytokines [92,
94]. Generally it can be said that ERK1/2 are preferentially activated in
response to growth factors and extracellular stimuli while p38 is more
responsive to stresses such as osmotic shock, ionizing radiation and
cytokines [95]. MAPKs can be present in several cell compartments, such as
the nucleus, cytoplasm, mitochondria and close to the cell membrane. Among
their targets are other kinases and transcription factors allowing them to
integrate signals and activate a variety of responses. While it can be difficult
to dissect the effects of MAPKs activation from a specific stimulus, it is known
that they can regulate mitosis, apoptosis, survival, differentiation, gene
expression and more. MAPKs involvement in human disease has been
proven and several kinases have been considered as targets of
pharmaceutical modulation [96]. Of note, cancers such as melanoma and
breast and ovarian tumors can be brought about by mutations in proteins
either participating in the MAPKs pathways or direct targets [97]. Inflammatory
related diseases such a COPD (chronic obstructive pulmonary disease),
rheumatoid arthritis and systemic lupus also show MAPKs dysregulation.
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Interestingly, neurodegenerative disease such as Alzheimer’s,
Parkinson’s and ALS (Amyotrophic lateral sclerosis) are characterized by p38
and ERK alterations. For example, it has been shown that in a model of
Alzheimer’s disease the oxidative stress induced by Amyloid beta
accumulation leads to p38 activation and tau protein phosphorylation [98].
The cardiovascular system is also regulated by MAPKs and these have been
considered as potential targets in cases of infarction, hypertrophy and heart
failure [99, 100]. Pharmaceutical companies are investigating small molecule
inhibitors or activators of MAPKs and several clinical studies are underway to
investigate whether these could prevent, treat or decrease the symptoms of
the diseases they are involved in.
In mammals, four splice variants of p38 kinase exist: p38α, p38β, p38γ
and p38δ [101]. P38α was first isolated as a 38 KDa protein that was rapidly
phosphorylated in a characteristic Thr-Gly-Tyr (TGY) motif following
application of pro inflammatory stimuli [102-105]. The four splice variant
proteins have a 60% identity in sequence, but can be differentially activated
by upstream kinases and have different target proteins. P38α and p38β are
widely expressed, while p38γ and p38δ are only expressed in certain cell
types. Because of the sequence similarity of the different p38 isoforms, it is
difficult to separately investigate the functioning of each. The perfect
homology in the TGY motif results in the impossibility to raise antibodies for
only one of the active isoforms. Therefore phosphop38 antibodies will bind to
all p38 isoforms. Further complicating the study of each isoform, small
molecule inhibitors also do not discriminate between isoforms.
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The extracellular signal regulated kinase subfamily is comprised of the
evolutionarily conserved ERK1 and ERK2 which have 83% amino acid identity
[95]. Similarly to the p38 isoforms, ERK1 and ERK2 have perfect homology in
their activating phosphorylation motif, resulting in antibodies that bind to both
active forms.
To our interest p38 has been found to be regulated by aging and
estrogen treatment in different cell and animal settings. In a 2011 study, Li et
al. hypothesized that p38, a key regulator of pro-inflammatory cytokine
biosynthesis, would be activated by the low grade inflammation that is
associated with the aging process [106]. By measuring cytokines and markers
of inflammation in the lungs of young (2mo) and old (20mo) C57BL/6J mice
they showed a significant increase of inflammatory markers with age [106].
They also measured p38 activation in the lung and whole brain homogenate,
showing the activation of p38 was doubled in the older mice, confirming their
initial hypothesis [106]. Furthermore, Yousin Suh measured age specific
changes in MAPKs expression and activity in the brain and liver of 2 mo and
26 mo female Fisher344 rats [107]. Again, p38 expression and activity was
increased by 2.5 fold in the aged brain while no change in expression was
measured in the liver [107]. In a separate study, the adrenal gland of 24-27
mo rats had increased levels of active p38 compared to younger animals
[108]. In contrast to that, age dependent inhibition of p38 activity was detected
in the cortex of 24 mo rats compared to 6 and 12 mo animals [109]. MAPKs
can be activated by extracellular stimuli and E2 has been shown to activate
p38 and ERK in a rapid, non-genomic way in isolated cardiomyocytes as well
as in neuronal cells [110] [111].
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P38 has also been shown to have a role in reproductive physiology,
and it is more highly activated in the granulosa cells of older patients [112].
The same study also examined cellular localization of p38 and found that
activated p38 was more highly present in the nucleus of younger cells, while it
mostly resided in the cytoplasm in granulosa cells of older patients [113]. The
authors concluded that oxidative stress might be the cause for the different
subcellular localization of p38, since reactive oxidative species (ROS) are
known to induce translocation of p38 to the cytoplasm and are abundant in
aged cells. In the cardiovascular system, activated p38 has been implicated in
a wide spectrum of pathologies, such as hypertrophy, infarction, and systolic
and diastolic heart failure [100, 114-116]. The signaling pathways that p38
regulates could be linked to its role in heart pathology including apoptosis,
pro-inflammatory gene regulation, myofilament modulation and remodeling of
matrix proteins [115]. Several clinical trials involving p38 inhibitors have not
yielded the positive results expected in regards to cardiovascular diseases,
however there have been more encouraging results in rheumatoid arthritis
treatment [100].
Overall it is well understood that MAPKs signaling plays an integral
role in aging, and their aberrant regulation might be involved in age-related
disorders. The molecular mechanisms by which p38 activation can be
detrimental are not well understood, but we can infer from the literature that
the age-dependent activation of MAPKs might be at least part of the cause for
cardiovascular disease in post-menopausal women.
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Figure 6. ERK and p38 signaling.
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EXPERIMENTAL DESIGN
ANIMAL PARADIGM
The Timing Hypothesis originated from clinical data and clearly points
to time after onset of menopause as an important factor in HT success.
Therefore, we designed an animal paradigm that allows us to discern the
relative contributions of age, length of E2 deprivation and subsequent E2
replacement over molecular and physiological responses (Fig. 7). The
literature on animal models of menopause indicates that rats are the most
appropriate non-primate animal model for menopause [117]. However, unlike
primates, aging rats do not undergo a rapid decline in E2 levels so bilateral
ovariectomy (OVX) is necessary to abolish endogenous E2, thereby ensuring
an equivalent hormonal milieu. Our preliminary data show that a
subcutaneous injection of 2.5 µg/kg E2 in aged (18mo) Fisher344 rats
achieves circulating E2 levels of 50.56+/- 8.78 pg/ml, which is within the
physiological range for post-menopausal patients receiving HT (17-75pg/ml;
[118, 119]). Importantly, this paradigm will allow us to draw conclusions on the
effects of duration of E2 deprivation prior to HT. Fisher344 rats (18mo; N =
10/group, total = 90) will be administered E2 or safflower oil (vehicle)
once/day x 3 days at 1 week, 4 weeks, 8 weeks or 12 weeks after OVX,
reflecting women who begin HT closer to menopause versus those who
waited for longer periods of time.

28

12 weeks
8 weeks

E2 x 3
E2 x 3

E2 x 3

Sac

OVX

Sac

Day 0

E2 x 3

Figure 7. Animal Paradigm.

29

Sac

1 week

Sac

4 weeks

HYPOTHESIS AND QUESTIONS
Estrogens are neuroprotective and cardioprotective for women, however
when administered long after menopause, they fail to improve their health.
This age related switch in estrogens’ effects after prolonged deprivation has
not been explained. It is possible that the estrogen receptors (ER) that
mediate the protective effects are modified following menopause and no
longer function as in the past. Phosphorylation is the most common protein
modification and it can fundamentally alter a protein’s activity. The ERβ
isoform of the receptor is highly expressed in the brain and heart and has
been shown to mediate protective neurological and cardiovascular effects.
Little is known about ERβ phosphorylation, but the Mitogen Activated Protein
Kinases can in vitro phosphorylate ERβ in its N-terminal domain. This part of
the protein mediates its interactions with coregulatory proteins that dictate its
function as a transcription factor. The MAPKs responsible for this modification
respond to cellular and extracellular stresses, which can increase with aging
and disease and have been shown to be sensitive to estrogens. Therefore, I
hypothesized that Mitogen Activated Protein Kinases are sensitive to age
and prolonged estrogen deprivation leading to a differential
phosphorylation of ERβ which results in altered transcriptional
regulation.
These are the questions I sought to answer:
1. Is phosphorylated ERβ present in vivo in the brain and heart? (see
Chapter III)
2. Does site specific phosphorylation of ERβ alter its activity as a
transcription factor? (see Chapter III)
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3. Does phosphorylation of ERβ alter its ability to bind to DNA? (see
Chapter III)
4. Is the activity of the MAPKs ERK and p38 sensitive to prolonged
estrogen deprivation and estrogen treatment? (see Chapter IV)
5. Is the expression of ERK and p38 dependent on prolonged estrogen
deprivation and estrogen treatment? (see Chapter IV)
6. Which ER mediates the effects of estrogen on MAPKs activation? (see
Chapter IV)
7. Can phosphorylated ERβ be detected and quantified in vivo? (see
Chapter V)
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CHAPTER III
PHOSPHORYLATION ALTERS ESTROGEN RECEPTOR Β-MEDIATED
TRANSCRIPTION IN NEURONS
Journal of Neuroendocrinology, 2015 Dec;27(12):861-71
INTRODUCTION
Nuclear steroid receptors are master regulators of a broad range of
physiological processes through their actions as ligand-activated transcription
factors. Estrogen receptors (ERα and ERβ) are members of this receptor
superfamily and their cognate endogenous ligand is 17β-estradiol (E2), which
is the major circulating form of estrogen in premenopausal women. ERα and
ERβ are widely expressed in a variety of tissues, although ERα is particularly
abundant in breast, uterus and ovary, due to its primary role in mediating the
reproductive-related effects of estrogens. By contrast, ERβ is highly
expressed in many non-reproductive tissues such as nervous, cardiovascular,
skeletal, gastric, and adipose tissues, and has been implicated in mediating
estrogens effects on anxiety, mood, and memory, as well as numerous other
physiological processes [15, 16, 40, 65, 120, 121]. Our basic understanding
of ERα structure, function, and signaling pathways has significantly advanced
in recent years, however similar aspects of ERβ function, especially in nonreproductive tissue/cell types, remain unclear.

The overall goal of these studies was to define the functional
consequences of post-translational modifications to ERβ, namely site-specific
phosphorylation, on its ability to transcriptionally activate gene promoter
activity in neuronal cells.
Post-translational modifications (PTMs) such as phosphorylation,
ubiquitination, acetylation, and sumoylation have been identified for several
nuclear steroid receptors, including ERs [122-126]. These modifications have
the potential to alter all aspects of ER function including ligand binding,
dimerization, protein:protein interactions, DNA binding and, ultimately, alter
ER-mediated transcription. Although several kinase consensus sites have
been predicted for ERβ, only a few have been experimentally confirmed [66].
Specifically, the serine residues S87 and S105 located in the N-terminal
domain of ERβ are highly conserved among the mouse, rat, and human,
suggesting that ERβ phosphorylation at these sites could be a common
regulatory mechanism across species [81]. The N-terminal domain of ERβ
exhibits greater than 80% homology across species and the specific amino
acid residues flanking S87 and S105 are highly conserved [127]. By contrast,
the N-terminal domain of ERβ has relatively low homology with ERα, which
could contribute to the divergent actions of the two receptors. These S87 and
S105 sites are targets of MAPKs (Mitogen Activated Protein Kinases) and the
specific MAPKs, P38 and ERK, have been shown to phosphorylate human
and mouse ERβ in vitro [81, 128]. Functionally, phosphorylation of these sites
increased recruitment of the coregulatory protein SRC-1 (steroid receptor
coactivator-1), while coincidentally increasing transcriptional activation at an
estrogen response element (ERE) [128].
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Phosphorylation of ERβ has been studied primarily in vitro using breast
tumor cell models. The only reports of detection of phosphorylation of ERβ in
vivo come from immunohistochemistry analysis of human breast cancer tissue
using a human-specific antibody generated against the phosphorylated S105
ERβ [81]. However, ERβ is highly expressed in non reproductive tissue such
as the brain and heart, and its phosphorylation would have important
functional consequences on those systems. Therefore, my first goal in these
studies was to determine whether ERβ is phosphorylated in vivo in the brain
as well as in the heart of female rats. Using PhosTagTM Acrylamide I was able
to detect several phosphorylated species of ERβ in the dorsal hippocampus
and left ventricle of the heart of aged (18 mo. Old) female rats. This, to my
knowledge, is the first report of phosphorylated ERβ detection outside of the
breast in any species.
Previous work by my laboratory showed that p38 kinase inhibition
altered ERβ-dependent activation of ERE and AP-1 (activator protein-1)
promoter activity in neurons [70]. However p38 kinase inhibitors are broadspectrum inhibitors and can affect multiple signaling pathways in the cell,
thereby making it unclear whether ERβ was a direct target of phosphorylation
by p38 in those studies. Furthermore ERβ phosphorylation states were not
determined. Therefore, in these studies I created phospho-mutants of ERβ to
directly assess the consequences of ERβ phosphorylation on its
transcriptional activity in neuronal cells. I hypothesized that phosphorylation
of ERβ at specific sites, S87 and S105, would alter ERβ mediated gene
regulation in neuronal cells, both directly at a canonical ERE site and also
indirectly through protein:protein interactions at an AP-1 site. I also tested
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whether phosphorylation of S87 and S105 altered the binding affinity of ERβ
to a canonical ERE sequence. Collectively, my results demonstrate that
phosphorylation of S87 and S105 altered both estrogen-independent and
estrogen-dependent ERβ mediated transcriptional regulation at ERE and AP1 sites in neuronal cells, but did not alter the DNA binding affinity to ERE
sequences. Taken together, these data suggest that altered kinase activity in
the brain, as occurs during aging, has the potential to alter the downstream
expression of ERβ gene targets resulting in fundamental changes in brain
function.
RESULTS
PHOSPHORYLATED SPECIES OF ERΒ ARE PRESENT IN THE DORSAL
HIPPOCAMPUS OF AGED FEMALE RATS.
The detection of phosphorylated ERβ in the brain and heart in vivo has
not been previously demonstrated, likely due to its relatively low expression
and the lack of commercially available phospho-specific antibodies targeting
rERβ. A powerful tool that has recently emerged is PhosTagTM, a phosphatebinding tag that slows the migration of phosphorylated protein during the
electrophoretic run on polyacrylamide gels [129]. Use of PhosTagTM
acrylamide results in the detection of several bands when analyzed by
Western Blot using specific antibodies for the protein of interest, and each
band represents the target protein with a different degree of phosphorylation.
For instance, higher bands indicate that the target protein contains several
phosphate groups, which result in a slower migration through the gel and is
visualized as a higher band shift. To verify the specificity of the
phosphorylated bands detected, protein samples can be treated with alkaline
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phosphatase (AP), which will dephosphorylate the protein and result in the
absence of detectable phosphorylated bands on the Western blot. The only
band detected will be a lower band representing the non-phosphorylated
protein of interest.
I tested whether phosphorylated ERβ is present in the dorsal
hippocampus and left ventricle of aged female rats to provide rationale for
assessing the functional consequences of phosphorylated ERβ in neuronal
cells. Estradiol (E2) is known to have direct effects on the dorsal
hippocampus, a brain region involved in cognition and memory formation and
a region where ERβ is more highly expressed than ERα [130, 131]. Because
E2 therapy is often prescribed to ameliorate the negative cognitive and
cardiovascular issues that accompany menopause, I used a model of
surgically-induced menopause followed by acute E2 treatment to test whether
1) phosphorylated ERβ is present in the brain and heart, and 2) E2 treatment
alters ERβ phosphorylation levels in the brain. Aged Fisher 344 rats (18 mo.
Old) underwent ovariectomy (OVX) followed by acute E2 or vehicle
administration for 3 days (see Methods).
Fig. 8 shows a representative PhosTagTM SDS-PAGE blot probed for
ERβ with the ERβ specific antibody. Phosphorylated ERβ was detected in the
dorsal hippocampus of both the vehicle and E2-treated animals (Fig. 8A,
arrow). Following AP treatment this same band disappeared, indicating that
the band that shifted was specific for phosphorylated ERβ. AP treatment did
not diminish the intensity of the lower band, which represents
unphosphorylated ERβ, however the higher band is very dark indicating that a
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large amount of ERβ in the aged female dorsal hippocampus was
phosphorylated to some degree (Fig. 8A).
In Fig.8B phosphorylated ERβ is detected in the left ventricle of aged
female rats. Conversely to the dorsal hippocampus, more than one band is
absent following AP treatment. This could have different explanation. First, it
is possible that an increasing amount of phosphates are bound to ERβ. This
would result in the several bands detected: the higher being ERβ with several
phosphates attached which would cause a slower electrophoretic run in the
PhosTagTM gel. The other possible explanation is that splice variants of ERβ
are present in the heart, and that those are also phosphorylated. ERβ2 is a
widely expressed splice variant which has as an additional 18 amino acid
insertion far from the antibody binding site, therefore it could recognize and
bind it as well [132-134]. ERβ2 protein has not been detected in the heart but
its mRNA has been detected in the cardiovascular system [134]. I hypothesize
that the lower band in the AP treated samples is ERβ1, the band above ERβ2
and bands that are only present in absence of AP treatment a combination of
phosphorylated species of ERβ1 and ERβ2.
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Figure 8. Expression of phosphorylated ERβ in the dorsal hippocampus
of aged female rats. Protein isolated from the dorsal hippocampus (50 μg)
was resolved using Phos-Tag TM SDS-PAGE electrophoresis and probed for
ERβ with the ERβ specific antibody (SC-150). Phos-TagTM binds phosphate
groups and increased protein phosphorylation retards gel migration. Alkaline
phosphatase (AP) treatment removes phosphate groups allowing the protein
to migrate further through gel. Aliquots of the same dorsal hippocampus
protein sample were treated with different amounts of AP. Arrow indicates
phosphorylated ERβ. Samples not treated with AP show upper band,
indicating presence of phosphorylated ERβ that is abrogated in samples
treated with either 30 or 60 units of AP.
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ERβ PHOSPHORYLATION ALTERS LIGAND DEPENDENT AND LIGAND
INDEPENDENT ACTIVATION OF ERE-MEDIATED TRANSCRIPTION IN
NEURONAL CELLS.
To study the functional effects of phosphorylation of ERβ in neurons, I
used site-directed mutagenesis to mutate S87 and S105 into alanine (A), a
residue that cannot be phosphorylated, or glutamic acid I, a residue that
resembles a phosphorylated serine because of its similar negative charge and
molecular bulk [135]. The expression vector constructs used in the transient
transfection analysis are listed in Table 1. ERβ acts as a transcription factor in
cis by directly binding to DNA at consensus ERE sequences and activating
downstream gene transcription. To test whether phosphorylation of ERβ alters
its ability to regulate ERE-mediated transcription, I transiently co-transfected
wild type (WT)-ERβ or one of the mutants listed in Table 1 with the reporter
construct ERE-tk-luc in a hippocampal-derived cell line (HT-22).
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Vector name Characteristics
Wild type

ERβ

Wild type ERβ

87E

Phospho mimetic at S87

87A

Phospho null at S87

105E

Phospho mimetic at S105

105A

Phospho null at S105

AA

Phospho null at S87 and S105

EE

Phospho mimetic at S87 and S105

AE

Phospho null at S87, phospho mimetic at S105

EA

Phospho mimetic at S87, phospho null at S105

Table 1. List of ERβ expression vectors.
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Phospho
mutants

Double
mutants

First I analyzed the ERE-mediated promoter activity for each of the
phospho-mutants with a single site mutated. A two-factor ANOVA analysis
revealed that there was a statistically significant interaction between plasmid
and treatment, demonstrating that the effect of E2 on ERE-mediated promoter
activity depends on whether ERβ is phosphorylated at serine 87 and/or 105
(Fig. 9A; F (5,74)= 9.790, p<0.001). Consistent with previous studies, WTERβ tended to increase ERE-dependent transcription in the absence of ligand
(an approximate 2 fold increase) and E2 treatment increased it to a much
greater statistically significant extent (an approximate 5.5 fold increase, Fig.
2A) [136]. I then analyzed the ERE-mediated promoter activity for each of the
phospho-mutant receptors. Mutation of ERβ at serine 87 had differential
effects on ERE-mediated promoter activity depending on whether it was
phospho-null or phospho-mimetic. First, mutation to alanine (87A, phosphonull) increased ERE-mediated promoter activity to a similar extent as WT-ERβ
in the absence of E2, whereas E2 treatment significantly increased EREmediated activity to a greater extent. These results suggest that
phosphorylation at this site hinders the E2-dependent activation of the
receptor. Interestingly, the opposite effect was observed for mutations at the
serine 105 site. In that case, the phospho-null mutation (105A) was not
different from WT-ERβ. By stark contrast, the phospho-mimetic (105E)
increased not only the E2-independent (by approximately 4 fold), but also the
E2-dependent, activation of ERβ.
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Figure 9. Effects of ERβ phosphorylation on ERβ-mediated promoter activity
at an ERE site. Hippocampal-derived (HT-22) cell lines were transiently cotransfected with an ERE-tk-Luciferase reporter construct and the wild type
ERβ or (A) single phospho-mutant ERβ expression vector (S87A, S87E,
S105A, S105E) or (B) double phospho-mutant ERβ expression vector
(S87A+S105A; S87E+S105E; S87A+S105E, S87E+S105A) (B). Cells were
treated with 100 nM E2 or vehicle (0.01% ethanol) for 15 hours. Data are
expressed as the mean percent change compared to empty vector control ±
SEM. Different letters denote statistically significant differences as calculated
with two-way ANOVA and Tukey post-hoc analysis (p<0.05).
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The previous experiments demonstrated the effects of a single amino
acid manipulation on ERE- and AP-1-mediated transcription. In those
experiments, the phosphorylation status of the opposing site was unknown
and entirely dependent on the endogenous kinase activity in the cell.
Therefore, in this next series of experiments I tested whether simultaneous
phosphorylation (i.e. S87E + S105E (EE)) or complete absence of
phosphorylation (i.e. S87A and S105A (AA)) at both serine residues could
further alter ERβ regulation. In addition, I also tested the effects on EREmediated transcription when one site was phosphorylated, but not the other
(i.e. S87A + S105E (AE); S87E + S105A (EA)). Each of the double mutant
vectors (see table 1) were transiently co-transfected with an ERE-tk-luc
reporter construct in HT-22 cells as described before.
A two-factor ANOVA analysis revealed a statistically significant
interaction between plasmid and treatment, once again indicating that E2
regulation of promoter activity depends on the phosphorylation status of both
ERβ S87 and S105 residues (Fig. 9, F( 5,78)= 5.271, p< 0.001). Figure 9B
demonstrates the effects of the double mutants on ERE-mediated promoter
activity. All of the double mutants increased ERE-mediated transcription in the
presence of E2, although the increase was greater when the two serine
residues had an opposite phosphorylation status (AE, EA, Fig. 9B). Moreover,
the AE mutation increased ERE-mediated activity by more than 2 fold in the
absence of ligand.
Overall, these data demonstrate that phosphorylation of ERβ at both
S87 and S105 has important functional consequences on its ability to
transcriptionally activate ERE-mediated promoters in neurons.
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ERβ PHOSPHORYLATION ALTERS LIGAND DEPENDENT AND LIGAND
INDEPENDENT ACTIVATION OF AP-1 DEPENDENT TRANSCRIPTION IN
NEURONAL CELLS.
Estrogen receptor β can also act as a transcription factor in trans by
tethering other transcription factors, thereby regulating a larger subset of
genes whose promoters might lack a consensus ERE. For instance, ERβmediated regulation at AP-1 sites requires ERβ interaction with transcription
factors of the Fos and Jun families. Similar to my observed results on EREmediated promoter activity, a two-factor ANOVA analysis revealed that there
was a statistically significant interaction between plasmid and treatment (Fig.
10A; F (5, 59)= 6.046, p< 0.001). First, WT-ERβ had a constitutive (ligand
independent) inhibition of AP-1-mediated promoter activity (an approximate
50% decrease, Fig. 10A), which showed a trend towards a decrease following
E2 treatment. These results are consistent with my previous reports of ERβ
repression of AP-1-mediated promoter activity in neuronal cells [70, 136].
Surprisingly, however, mutation of S87 or S105 to any form (phospho-null or
phospho-mimetic) completely abolished the ligand independent inhibition of
AP-1-mediated transcriptional regulation, yet the E2-induced reduction was
preserved. These results suggest that S87 and S105 are critical residues
mediating the ligand independent actions of ERβ at an AP-1 site.
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Figure 10. Effects of ERβ phosphorylation on ERβ-mediated promoter
activity at an AP-1 site. Hippocampal-derived (HT-22) cell lines were
transiently co-transfected with an AP-1-tk-Luciferase reporter construct and
the wild type ERβ or (A) single phospho-mutant ERβ expression vector
(S87A, S87E, S105A, S105E) or (B) double phospho-mutant ERβ expression
vector (S87A+S105A; S87E+S105E; S87A+S105E, S87E+S105A) (B). Cells
were treated with 100 nM E2 or vehicle (0.01% ethanol) for 15 hours. Data
are expressed as the mean percent change compared to empty vector control
± SEM. Different letters denote statistically significant differences as
calculated with two-way ANOVA and Tukey post-hoc analysis (p<0.05).
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I next tested whether simultaneous phosphorylation (i.e. S87E + S105E
(EE)) or complete absence of phosphorylation (i.e. S87A and S105A (AA)) at
both serine residues could further alter ERβ regulation at an AP-1 site. The
regulation of AP-1-mediated transcription by double ERβ mutants is shown in
Figure 10B. Surprisingly, the ligand independent inhibition of AP-1 was
restored when both S87 and S105 were concurrently mutated, while the
single mutation of those same sites abolished the constitutive inhibition of AP1 regulation by WT-ERβ (Fig. 10B). Moreover, E2 significantly inhibited the
constitutive repression to a greater extent when S105 was mutated to a
phospho-mimetic I regardless of the phosphorylation status of S87 (Fig. 10B;
F (5,70)= 3.741, p< 0.005).
Overall, I show that ERβ regulation of AP-1 dependent transcription is
fundamentally altered by single, but not double, mutation of S87 and S105.
PHOSPHORYLATION OF ERΒ ALTERS TAMOXIFEN EFFECTS ON ERE
AND AP-1 TRANSCRIPTION IN NEURONAL CELLS.
Next, I tested whether phosphorylation of ERβ alters the effects of
tamoxifen (TAM), a known selective ER modulator (SERM). TAM can be both
agonistic and antagonistic, depending on cell type, ER subtype, and promoter
response element [137-141]. I have previously shown than TAM abrogates
the constitutive activation of ERE in HT-22 neuronal cells, and this was also
true for some of the phospho-mutants tested (Fig. 11) [136]. Similar to the
previously described experimental results, a two-factor ANOVA revealed a
significant interaction between the two factors, plasmid type and TAM
treatment (F (5, 71) = 12.978, p< 0.001). Specifically, TAM treatment
completely eliminated the constitutive ligand-independent activation (i.e.
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vehicle-treated) of ERE-mediated transcription (Fig. 11A). Further,
phosphorylation of S105 (105E) increased constitutive activity to the greatest
extent (>400%), and also increased TAM dependent activation of EREmediated transcription compared to wild type ERβ (Fig. 11A). These results
suggest that phosphorylation of S105 would alter transcription of ERE
regulated genes following TAM treatment.
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Figure 11. Effects of tamoxifen treatment on ERβ or ERβ mutant-mediated
promoter activity at an ERE or AP-1 site. Hippocampal-derived (HT-22) cell
lines were transiently co-transfected with an (A) ERE-tk-Luciferase or (B) AP1-tk-Luciferase reporter construct and the wild type ERβ or phospho-mutant
ERβ expression vector (S87A, S87E, S105A, S105E). 24 hours following
transfection, cells were treated with 100 nM 4-OH-tamoxifen (TAM) or vehicle
(0.01% ethanol) for 15 hours. Transfection efficiency was normalized using a
second renilla luciferase reporter construct (rLUC) in all experiments. Data are
expressed as the mean percent change in fLUC/rLUC compared to empty
vector control ± SEM taken from 4 independent experiments with 6
replicates/experiment. Different letters denote statistically significant
differences as calculated with two-way ANOVA and Tukey post-hoc analysis
(p<0.05).
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Our previous studies showed that TAM abolished the observed ligand
independent inhibition of AP-1 activity by ERβ. The current studies confirm
that TAM does abolish the ligand independent inhibition of AP-1 activity for
the WT-ERβ (Fig. 11B). However, mutation of S87 or S105 alone abolished
the ligand independent repression of AP-1-mediated transcription (see Figs.
10, 11B vehicle), and treatment with TAM did not have any additional effects.
Phosphorylation of ERβ does not alter binding to an ERE sequence
Phosphorylation of nuclear receptors has previously been shown to
alter their binding affinity for consensus response elements, such as an ERE,
in the promoter regions of their target genes. Moreover, I have previously
shown that WT-ERβ can bind to consensus ERE sequences both in the
absence and presence of E2, but the effects of phosphorylation of S87 or
S105 have never been investigated [70, 136]. Therefore, I tested whether
phosphorylation of ERβ at S87 or S105 altered its ability to bind to consensus
ERE sequences using electromobility shift assays. After autoradiography, I
observed that all receptor proteins produced an equally strong shift in the
position of the 32P-labeled ERE oligonucleotide, demonstrating that
phosphorylation of S87 and S105 did not affect ERβ:DNA binding to that
consensus sequence (Fig. 12).
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Figure 12 Effects of S87 and S105 phospho-mutation on DNA binding to a
consensus ERE sequence. Vitellogenin ERE consensus sequence was 32Pend labeled and incubated with in vitro translated wild type or phospho-mutant
ERβ protein receptor lysates. Receptor lysates were incubated with 100 nM
E2 or vehicle for 16 hr. prior to 30 min. incubation with 32P-labled ERE
oligonucleotide and resolved on a 6% retardation gel. Gels were dried and
exposed to a phosphoImager screen for 4 hours prior to imaging. Specific
binding was confirmed by incubating with a scramble radiolabeled DNA
sequence (lane 2) or by addition of a 1000X unlabeled ERE oligonucleotide
prior to addition of radiolabeled vitellogenin ERE (lane 3). (Neg: negative
control, no lysate). Relative densitometry of gel bands taken from six
independent experiments were quantified using IMAGE J (NIH, Bethesda,
MD, USA). The data are reported as the mean ± SEM density of pixels. Twoway ANOVA analysis indicated no statistically significant differences.
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Unlabeled excess (500 or 1000x) of the same 32P-ERE oligonucleotide
competed effectively for ERβ binding and no shift was observed when the
receptors were incubated with a

32

P-labeled scrambled DNA sequence

Densitometry was used to quantify the band width and there were no
statistically significant differences in the average densities of each band
between the WT-ERβ and the phospho-mutants, indicating that
phosphorylation at S87 or S105 does not affect ERβ binding affinity to
consensus ERE sequences (Fig. 12). These experiments were repeated at
minimum of 10 times to account for lane-to-lane variability between gels, and
the average band density from all gels combined was calculated to determine
if phospho-mutation and/or ligand affected ERE binding. I did not observe any
statistically significant differences in average band density between vehicle or
E2 treatments for either WT-ERβ or the ERβ phospho-mutants, which is
consistent with my previous reports for WT-ERβ [70, 136].
DISCUSSION
The overall objective of these studies was to determine the
consequences of ERβ phosphorylation on its functional capacity to act as a
transcription factor at known promoter enhancer sites in neurons. Further, I
hypothesized that phosphorylated ERβ would be detectable in the brain of
aged animals, due to the potential alterations in kinase activity that can occur
with aging [107, 142-145]. My data demonstrated the novel finding that
phosphorylated ERβ is not only present in the brain of aged females, it is
likely the major form of ERβ expressed in the dorsal hippocampus and
phosphorylation tended to increase following E2 treatment. These data
provide strong evidence for the physiological relevance of my functional in
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vitro data, which together demonstrated that phosphorylation of ERβ at
specific serine residues altered its ability to activate and/or repress promoter
activity in neurons. Collectively, these data suggest that age-related changes
in hormonal milieu and cellular kinase activity could impact the expression of
ERβ-regulated genes, such as those mediating stress, anxiety, and cognitive
function.
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wtERβ

ERE (DNA binding)
constitutive
E2 dependent
↑
↑↑

S87A

↑

↑↑↑

S87E

↑

↑↑

S105A

↑

↑↑

S105E

↑↑

↑↑↑

AP1 (Prot-Prot interaction)
constitutive
E2 dependent
↓
↓↓

−
−
−
−

↓↓
↓↓
↓↓

↓

Table 2. Schematic summary of reporter assay results. Arrows indicate
direction of change in relation to wild type ERβ. In grey are highlighted the
instances of differences between each mutant compared to wild type ERβ.
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Post-translational modifications of nuclear steroid receptors have been
widely investigated and these modifications are known to regulate their
signaling abilities [66, 122, 125, 126]. Structurally, ERβ is similar to other
members of the nuclear steroid receptor superfamily. The N-terminal A and B
domains are collectively defined as the AF-1 (Activation Function-1, or Nterminal transactivation) domain, which is a highly variable domain amongst
the steroid receptor family and is fundamental for binding coregulatory
proteins that assist in transcriptional activation or repression [70, 136].
Phosphorylation of mouse ERβ at the N-terminal serine 106 and 124 has
previously been shown to mediate ligand independent recruitment of the
coregulatory protein SRC-1 (steroid receptor coactivator 1) and alter its
subsequent transcriptional activity at an ERE in COS-1 cells [128]. In those
studies, overexpression of SRC-1 significantly increased ligand independent
activation at an ERE site. This effect was dependent on the MAPK
phosphorylation of S106 and S124, as the double phospho-null mutation
(S106A/S124A) completely abolished the SRC-1-induced activation at an
ERE. However, that study did not evaluate the effects of S106A or S124A in
the presence of ligand (E2), or the transcriptional activity at an ERE resulting
from a S106/S124 phospho-mimetic (i.e. mutation to glutamic acid). In my
studies the single mutation of S87A significantly increased E2-induced
transcription at an ERE, but there was no effect in the absence of E2.
Moreover, there was no difference in ERE-mediated transcription when S87
and S105 were both phospho-null (87A/105A) compared to WT-ERβ. The
discrepancies between my results and the previously reported could be due to
the overexpression of SRC-1 in those studies. In addition, it is possible that
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there is a differential endogenous expression of SRC-1 in neurons or that ERs
interact with different set of proteins depending on cell-type, resulting in
altered signaling.
A similar study evaluated the effects of phosphorylated human ERβ at
S105 in cancer cell lines [81]. In that study, phosphorylation of hERβ at S105
inhibited breast cancer cell invasion and migration in vitro, suggesting that
phosphorylation of ERβ at S105 mediates the anti-proliferative action of ERβ
in the breast. [81, 128]. Moreover, phosphorylated S105 ERβ has been
detected both in benign and invasive breast cancer tissue samples using a
human-specific phosphoS105 antibody; however no studies to date have
detected the presence of phosphorylated ERβ in the brain. My results using
neuronal cells showed that the phospho-mimetic S105E significantly
increased both ligand independent and ligand dependent transcriptional
activation at an ERE compared to WT-ERβ, whereas conversely, the opposite
phospho-null mutation of S105A had no effect. The LBD of ERβ lies between
residues 223-457, suggesting that phosphorylation of S87 or S105 is unlikely
to alter ligand binding. However, cross talk between the N-terminal and Cterminal domain has been demonstrated, suggesting that altered ligand
binding is a possible mechanism for phosphorylation-mediated changes in
transcriptional activity [9].
It is well accepted that ERβ has lower transactivation ability at an ERE
site compared to ERα and my data suggest that this discrepancy could be
partly explained by the phosphorylation status of ERβ in the N-terminal AF-1
domain [137]. For instance, phosphorylation of the N-terminal domain could
alter the ability of ERβ to bind consensus ERE sites, thereby allowing
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preferential binding of ERα to those same sites. This concept is supported by
the observation that various types of post translational modifications have
been shown to alter DNA binding in other contexts. For example, acetylation
of ERα at two lysine residues in the DBD enhanced its ability to bind to an
ERE [146]. By contrast, sumoylation of estrogen-related receptor alpha
(ERRα) at two sites in the N- terminal domain did not affect its DNA binding
ability, yet still altered its transcriptional activity [147]. My results add to
existing evidence supporting the idea that post translational modifications in
nuclear receptors at regions distant to the DBD alters their ability to modulate
transcription, without affecting DNA binding.
Perhaps the most interesting results from this study were the effects of
ERβ phosphorylation at an AP-1 site. I have previously shown that ERβ exerts
strong transcriptional repression at an AP-1 site in neuronal cells in the
absence of ligand and the results presented here indicate that this might
depend on phosphorylation of the N-terminal domain [70, 136]. The single
mutation of either S87 or S105 completely abolished ligand independent
inhibition of AP-1 mediated transcription compared to WT-ERβ. However, AP1 mediated transcription was equally repressed with WT-ERβ as it was with
double mutations of AA, EE, or AE. Notably, only the 87E/105A mutation
showed a significant difference from the other mutants, suggesting that S87
phosphorylation status is the critical serine residue for mediating ERβ-induced
repression at an AP-1 site. The precise dynamics of p38 and ERK
phosphorylation of ERβ are unknown and the folding of singly phosphorylated
ERβ could render the other site inaccessible to the kinase. Nevertheless, my
data suggests that a single phosphorylation change in either S87 or S105
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abrogates the ligand independent inhibition of AP-1, whereas no effect is
observed due to concurrent phosphorylation of both sites. This could be
explained by altered ERβ protein-protein interactions with Jun/Fos proteins or
with other co-regulatory proteins recruited to the AP-1 complex, such as p160,
based on evidence that phosphorylation alters coregulatory protein
recruitment to ERβ [128]. The next step will be to determine which of these
sites are phosphorylated in vivo and the precise molecular environment that
facilitates those phosphorylation changes.
Recently, Vivar and colleagues identified 3 classes of ERβ target
genes and discovered that the majority of genes (453) fell into the Class I
category, which were genes regulated by unliganded ERβ [148]. Further, the
Class I genes showed a high enrichment for AP-1 binding sites,
demonstrating that ligand independent repression of AP-1-mediated promoter
activity is a common mechanism of ERβ signaling. Similarly, Zhao et al.
showed that over 60% of ERβ interacting regions in MCF-7 breast cancer
cells contain an AP-1 site [149] . Together these studies underscore the
significance of my findings that ERβ ligand independent activity at an AP-1
site is abolished when the N-terminal domain is phosphorylated. Aging in
women results in dramatic declines in circulating estrogens raising the
possibility that the ligand-independent actions of ERβ could play a prominent
role in regulating gene transcription in the aging brain.
My studies were limited to the investigation of just one type of posttranslational modification (phosphorylation) at specific serine residues.
However, there is evidence that other post-translational modifications of ERβ
could also be present, such as acetylation and sumoylation, and these
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modifications can create cross talk between different residues of the receptor.
For example, phosphorylation at S305 on ERα inhibits subsequent acetylation
at K303 leading to enhanced transcriptional regulation [150]. Moreover,
phosphorylation of S94 and S106 on mERβ leads to recruitment of
ubiquinating enzymes to the AF-1 domain resulting in enhanced degradation
of the receptor [151]. Future studies are required to determine the precise
mechanisms and consequences resulting from post-translational
modifications acting in concert to modulate overall ERβ function. My in vitro
studies were conducted using rat ERβ expression vectors in a mouse-derived
neuronal cell line. Given the high degree of homology between rat and mouse
ERβ, I expect that similar results would be obtained using rat neuronal cell
lines or primary neurons derived from either species [127]. However, it is
important to consider these results in this context as both brain-region and
species-specific effects of ERβ have been observed [152, 153].
Tamoxifen (TAM) has been described as a partial antagonist due to its
cell-type specific effects [139, 141, 154-157]. Relevant to these studies, TAM
action in the brain has been shown to block the neuroprotective effects of E2,
confirming that the beneficial effects of E2 are mediated by classical estrogen
receptors [120]. In addition, TAM can activate numerous second messenger
signaling pathways, including MAPK, thereby potentially phosphorylating and
altering ERβ transcriptional activity [158]. My results demonstrated that TAM
worked as an antagonist of both the WT and phosphorylated forms of ERβ by
preventing the ligand independent increase in ERE-mediated transcription.
Consistent with my previous studies, TAM also blocked the ligand
independent repression of WT-ERβ at an AP-1 site. The ligand binding
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domain (LBD) of ERα and ERβ is more conserved than other domains and XRay crystallography studies have shown that both receptors bind several
types of selective estrogen receptor modulators (SERMs), including TAM
[159]. The structure of TAM complexed with the ERα or ERβ LBD have been
resolved and TAM:LBD binding resulted in conformational changes that
inhibited subsequent binding of coactivator proteins, pointing to a clear
mechanism for TAM antagonism [160, 161].
In summary, my results show that phosphorylation of ERβ alters its
function in neuronal cells both in a ligand dependent and independent
manner, and that ERβ is phosphorylated in vivo in the hippocampus. My work
highlights the importance of further understanding the effects of posttranslational modifications on nuclear steroid receptors, as these
modifications fundamentally alter their function as transcription factors and
could result in clinically important physiological changes.
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CHAPTER IV
DIFFERENTIAL EFFECTS OF E2 ON MAPK ACTIVITY IN THE BRAIN AND
HEART OF AGED FEMALE RATS
PLOS ONE, February 2016 under review
INTRODUCTION
Clinical and basic science studies have shown that estrogens are
neuroprotective and cardioprotective. Treatment with estrogens (ET) can
reduce the incidence of Alzheimer disease, improve survival following
ischemic stroke, improve learning and memory, and reduce anxiety and mood
disorders [23-25, 36-38, 155]. Moreover, women are less likely to develop
heart disease than men, but this advantage is lost after menopause
presumably due to a significant reduction in circulating estrogens [41-43].
Clinical correlates have indicated that the decline of circulating estrogens
coincident with menopause leads to an increased risk of coronary heart
disease, atherosclerosis, hypertension, stroke, neurodegenerative disease,
cognitive decline, and mood disorders. However, the first large scale clinical
trial designed to assess the health benefits of ET in postmenopausal women
(The Women’s Health Initiative (WHI)) was prematurely suspended because
of an unexpected increased risk of stroke and coronary heart disease among
the participants [59].

Subsequent analysis of the clinical data revealed that the age of the
participants significantly affected the outcome. Women who began ET at the
time of menopause or within 10 years had significant reductions in heart
disease and overall mortality [162]. This observation was coined the “Timing
Hypothesis”, and postulated that ET administration is beneficial for early
postmenopausal women, but detrimental in late postmenopausal women.
Importantly, the underlying molecular mechanisms for these observations
remain undetermined.
The actions of estrogens are mediated primarily by estrogen receptor
(ER) α and ERβ. Both receptors can mediate the neuroprotective and
cardioprotective effects of estrogens [16, 25, 45, 46, 51, 155, 163]. Estrogens
bind ERs to regulate gene transcription through classical genomic pathways,
or by modulating cell signaling pathways such as the MAPKs (mitogen
activated protein kinases) ERK (extracellular signal-regulated kinase) and p38
[113, 164-170]. Moreover, aging alone modulates similar cell signaling
pathways independent of estrogens [107, 110, 113, 143, 144, 169, 171, 172].
One possibility for these age-related changes is that MAPKs are sensitive to
proinflammatory and oxidative stimuli, which are increased with age [173].
These converging data suggest that MAPK signaling could be a molecular
mechanism underlying the discrepant effects of ET in postmenopausal
women.
MAPK family members are activated by phosphorylation at their
threonine-x-tyrosine phosphorylation site motif. MAPKs activation is the last of
a three step activation cascade from MAP3K to MAP2K to MAPK. Once
phosphorylated (i.e. activated) they in turn phosphorylate substrate proteins at
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serine or threonine residues in specific recognition sequences [91]. The
knowledge of the activators, substrates and functions of MAPKs are ever
expanding, however when they were first discovered they were deemed
stress-activated protein kinases (SAPKs) because of their responsiveness to
toxins, physical stresses and inflammatory cytokines [92, 94]. Generally,
ERK1/2 are preferentially activated in response to growth factors and
extracellular stimuli, while p38 are more responsive to stresses such as
osmotic shock, ionizing radiation and cytokines [95]. MAPKs can be present in
several cell compartments, such as the nucleus, the cytoplasm and close to
the cell membrane, thereby allowing them to integrate signals to coordinate a
variety of physiological responses including mitosis, apoptosis, survival,
cellular differentiation, and gene expression.
Activated MAPKs target a wide pool of proteins due to sequence
variation in the conserved phosphorylation motif and in the availability of
docking sites on their protein targets. The strongest requirement is the
presence of a proline directly at the C- Terminus of the target protein
phosphorylation site and this feature is a shared requirement for both p38 and
ERK kinases. Another characteristic feature differentiating the downstream
effects of MAPKs is the presence of docking sites in their substrates; the best
characterized being D-sites and F-sites. ERK and p38 phosphorylate different
target proteins, leading to differential downstream effects because of their
heterogeneous recognition motif and respective preference for D- and F- sites
in the targets [93]. Interestingly, 30% of human proteins have at least one
MAPK phosphorylation site, yet few have the required docking sites to
facilitate phosphorylation by MAPK family members.
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The overall goal of this study was to quantify the total expression and
activation of MAPKs (ERK and p38) in the brain and heart of aged female rats
subjected to a paradigm designed to model the tenets of the Timing
Hypothesis (see Fig.13). I hypothesized that the combination of age and low
circulating estrogens alters the expression and activation of p38 and ERK
kinases in the brain and heart. To test this hypothesis, I used a rat model of
surgically-induced menopause and quantified changes in kinase activity
following varying lengths of E2 deprivation. My data revealed age- and E2dependent effects on kinase activity suggesting a potential mechanism
explaining the variable effects of E2 following menopause.
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Figure 13. Diagram of the animal paradigm. Female Fisher 344 rats were
ovariectomized at day 0 (= 18 months old) and subjected to increasingly
longer periods of hormone deprivation (1, 4, 8, and 12 weeks). Following the
assigned length of deprivation, animals were treated with either vehicle
(safflower oil) or 17-estradiol (E2; 2.5 μg/kg) by subcutaneous injection once
daily for 3 consecutive days (n=10/treatment group/deprivation time). Animals
were euthanized 24 hours following the last treatment.
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RESULTS
LENGTH OF E2 DEPRIVATION AND SUBSEQUENT E2 TREATMENT
ALTERS ERK AND P38 KINASE ACTIVITY IN THE BRAIN AND HEART OF
AGED FEMALE RATS.
I first tested whether the effects of E2 treatment on ERK and p38
kinase activity would depend on the length of time aged animals were
deprived of circulating E2 (i.e. time post-ovx). I measured the ratio of
phosphorylated and total ERK and p38 proteins as a measure of kinase
activity in 3 distinct brain regions (hypothalamus, dorsal hippocampus, ventral
hippocampus) and in the left ventricle of the heart. The hypothalamus
regulates homeostasis, thermoregulation and stress response which are often
dysregulated in post-menopausal women [174]. The hippocampus is
functionally divided in two regions, dorsal and ventral [175] and both regions
express ERs. The dorsal hippocampus (DH) mediates cognitive functions,
while the ventral hippocampus (VH) mediates processes associated with
emotional memory and stress [175]. In addition, I focused on the heart
because the likeliness of developing heart disease increases in women postmenopause, and sex differences in cardiovascular disease are well
characterized. The left ventricle (LV) is the main pumping chamber of the
heart and it is most commonly subjected to diseases that accompany aging,
such as hypertrophy. Estrogen receptors are highly expressed in the LV and
the cardioprotective effects of E2 treatment are evident in the LV [163, 176,
177].
Brain – Hypothalamus. A two-factor ANOVA analysis revealed a
significant interaction between length of E2 deprivation and subsequent E2
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treatment (all F-values reported in Table 3), demonstrating that the effects of
E2 are dependent on when it is administered following prolonged periods of
E2 deprivation. Total ERK protein increased in E2-treated animals at the 12week post-OVX time point, yet total protein in both groups remained stable at
all other time points (Fig. 14A). Conversely, E2 treatment had a dramatic
effect on the amount of phosphorylated ERK, which is an indicator for the
active form of the protein. E2 treatment significantly decreased the amount of
phosphorylated ERK to levels that were barely above detection at the 8- and
12-week post-OVX time points (Fig. 14B). The ratio of phosphorylated ERK
to total ERK protein was significantly lower at all time points in E2-treated
animals (Fig. 14C), representing a large magnitude shift from baseline
compared to vehicle-treated controls (Fig. 14D).
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Figure 14. Effects of age and E2 treatment on ERK protein expression and
activation in the hypothalamus. Total ERK protein (A), phosphorylated ERK
(B), calculated ratio of phospho:total-ERK (C), and percent change from
vehicle following E2 treatment (D). Data are expressed as mean fold change
 SEM compared to vehicle-treated animals at one week post-OVX (A-C). An
* indicates statistically significant difference from 1-week time point; #
indicates significant difference within the same time point.
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By stark contrast to ERK activity in the hypothalamus, total p38 protein
was unchanged over time and with treatment (Fig. 15A); however
phosphorylated p38 increased 3-fold at the 12-week time point in both vehicle
and E2-treated groups (Fig. 15B). The ratio of phospho:total p38 was not
altered by E2 treatment (Fig. 15C), however it is notable that it was increased
by 170% in the E2-treated animals at 1-week post-OVX compared to vehicle
treated animals.
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Figure 15. Effects of age and E2 treatment on p38 protein expression and
activation in the hypothalamus. Total p38 protein (A), phosphorylated p38 (B),
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Brain - Dorsal hippocampus. I then measured ERK and p38 protein
and phosphoprotein in the dorsal hippocampus (Figs.16, 17). Similar to the
results observed in the hypothalamus, a two-factor ANOVA revealed a
significant interaction between length of E2 deprivation (i.e. time post-OVX)
and subsequent E2 treatment (Table 3). E2 treatment significantly decreased
phosphorylated ERK at the 1-week time point, yet there were no changes in
total ERK protein in either group (Fig. 16A, B). The ratio of phospho:total ERK
was significantly lower than vehicle-treated animals at 1-week post-OVX (Fig.
16C) and the overall levels of phosphoERK were consistently lower in E2treated animals across the treatment paradigm (Fig. 16D).
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Figure 16. Effects of age and E2 treatment on ERK protein expression and
activation in the dorsal hippocampus. Total ERK protein (A), phosphorylated
ERK (B), calculated ratio of phospho:total-ERK (C), and percent change from
vehicle following E2 treatment (D). Data are expressed as mean fold change
 SEM compared to vehicle-treated animals at one week post-OVX (A-C). An
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Next, I measured p38 expression and activation in the dorsal
hippocampus (Fig. 17). A two-factor ANOVA analysis revealed a significant
main effect of time post-OVX, yet no significant interaction suggesting the two
variables were not dependent on each other (Table 3). Similar to ERK, E2
treatment significantly inhibited phospho-p38 levels 1 week post-OVX (Fig.
17B), yet the ratio of phospho:total p38 was not significantly different at any
time point (Fig. 17C, D).
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Figure 17. Effects of age and E2 treatment on p38 protein expression and
activation in the dorsal hippocampus. Total p38 protein (A), phosphorylated
p38 (B), calculated ratio of phospho:total-p38 (C), and percent change from
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Brain – Ventral hippocampus. A two-factor ANOVA revealed a
significant interaction between length of E2 deprivation and subsequent E2
treatment, similar to the results from the other brain regions (hypothalamus
and dorsal hippocampus) (Table 3). Specifically, total ERK protein was
significantly decreased at 4 weeks post-OVX in both vehicle and E2-treated
animals, and these levels increased back to the levels observed at 1-week
post-OVX by the 8 and 12-week time points (Fig. 18A). E2 treatment
decreased phosphoERK by 70%, at 1-week post-OVX, but both vehicle and
E2-treated animals had significantly lower levels of phospoERK at the 4 and 8
weeks post-OVX time points (Fig. 18B). Interestingly, the ratio of
phospho:total ERK was not different between treatment groups or with longer
periods of E2 deprivation (Fig. 18C) and this was likely due to parallel
changes that occurred in total available ERK protein. The strong inhibitory
action of E2 on ERK activation was only present at the early E2 deprivation
time point (1 week post-OVX), while at later time points (4 and 8 weeks postOVX) E2 treatment increased ERK activation (Fig.18D).
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Figure 18. Effects of age and E2 treatment on ERK protein expression and
activation in the ventral hippocampus. Total ERK protein (A), phosphorylated
ERK (B), calculated ratio of phospho:total-ERK (C), and percent change from
vehicle following E2 treatment (D). Data are expressed as mean fold change
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There were few observed differences between treatment groups or with
length of E2 deprivation in total or phospho-p38 levels (Fig. 19A, B). A twofactor ANOVA revealed no significant interaction between the two factors, but
there was a significant main effect of time post-OVX (Table 3). E2 treatment
significantly decreased the amount of total p38 protein at 12-weeks post-OVX
(Fig. 19A) without any corresponding change in the levels of phospho-p38
(Fig. 19B). The ratio of phospho:total p38 was also significantly decreased
after 8 weeks of E2 deprivation, but there was no difference between
treatment groups (Fig. 19C). Overall, E2-treated animals had lower
phosphorylated levels of p38 compared to vehicle treated animals until the 12week post-OVX time point. At 12 weeks post-OVX there was a dramatic
reversal with E2-treated animals having 88% higher levels of phosphorylated
p38 compared to vehicle-treated animals (Fig. 19D).
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Figure 19. Effects of age and E2 treatment on p38 protein expression and
activation in the ventral hippocampus. Total p38 protein (A), phosphorylated
p38 (B), calculated ratio of phospho:total-p38 (C), and percent change from
vehicle following E2 treatment (D). Data are expressed as mean fold change
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Heart – Left ventricle. Total ERK protein levels increased 12 weeks
post OVX in the E2-treated animals compared to the vehicle-treated animals
(Fig. 20A). In contrast to results obtained in the brain, length of E2 deprivation
(i.e. age alone) had the most striking effect on ERK activation, while E2
treatment had a modest, yet statistically significant effect. Moreover, a twofactor ANOVA revealed a significant interaction between length of E2
deprivation and subsequent E2 treatment (Table 3), demonstrating that the
effects of E2 replacement on ERK activity are altered following prolonged
periods of time post-OVX in both the heart and brain. Specifically, phosphoERK significantly decreased in both vehicle- and E2-treated groups at 4 and 8
weeks, yet there was a dramatic rebound in phospho-ERK in the E2-treated
animals after 12 weeks of E2 deprivation (Fig. 20B). However, after
comparing the ratio of active to total ERK it is clear that the length of E2
deprivation was the most important factor regulating ERK activity (Fig. 20C),
as both treatment groups showed significant declines (80% decrease) at 4
and 8 weeks that returned to baseline by 12 weeks (Fig. 20D). Notably, E2
treatment led to even further declines in active ERK (to nearly undetectable
levels) at 4 and 8 weeks post-OVX (Fig. 20D).
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Figure 20. Effects of age and E2 treatment on ERK protein expression and
activation in the left ventricle. Total ERK protein (A), phosphorylated ERK (B),
calculated ratio of phospho:total-ERK (C), and percent change from vehicle
following E2 treatment (D). Data are expressed as mean fold change  SEM
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Total p38 protein levels were not significantly altered in the heart in my
paradigm (Fig. 21A). However, a two-factor ANOVA analysis revealed a
significant interaction between the two factors, E2 treatment and length of
time post-OVX, on the levels of phospho-p38 in the heart. Consistent with the
observations for ERK, p38 activation decreased with longer periods of
deprivation post-OVX regardless of treatment in the heart (Fig. 21C). There
was a strong main effect of time post-OVX, as the phospho:total p38 declined
by more than 40% by the 4-week time point (Fig. 21C). These lower levels
were stable up to 12 weeks post-OVX, in E2 and vehicle treated animals, in
contrast with ERK whose activation levels were restored 12 weeks post-OVX.
Although E2-treatment significantly decreased phospho-p38 at 8 weeks postOVX, this effect did not have a major impact on the amount of active p38 (Fig.
21B, C, D).
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Figure 21. Effects of age and E2 treatment on p38 protein expression and
activation in the left ventricle. Total p38 protein (A), phosphorylated p38 (B),
calculated ratio of phospho:total-p38 (C), and percent change from vehicle
following E2 treatment (D). Data are expressed as mean fold change  SEM
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LENGTH OF E2 DEPRIVATION AND SUBSEQUENT E2 TREATMENT
ALTERS ERK AND P38 MRNA EXPRESSION
To determine if steady-state mRNA expression paralleled the observed
changes in protein levels, I measured ERK (Fig. 22) and p38 (Fig. 23) mRNA
in each brain region and in the left ventricle of animals subjected to my E2deprivation paradigm. A two-factor ANOVA revealed statistically significant
differences between treatment groups in the hypothalamus (Fig. 22A) and the
heart (Fig. 22D), but not in either region of the hippocampus (Fig.22B, C).
Treatment with E2 increased ERK mRNA 1-week post-OVX, (Fig. 22A,
dashed line), however ERK mRNA levels increased progressively over time
and this age-related increase was prevented by E2 treatment (Fig. 22A).
Similarly, prolonged periods of E2 deprivation increased ERK mRNA in the
heart and this was significantly decreased following E2-treatment at the 12
weeks post-OVX time point (Fig. 22D).
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Figure 22. Effects of age and E2 treatment on ERK mRNA expression. ERK
mRNA was measured using RT-qPCR in the hypothalamus (A), dorsal
hippocampus (B), ventral hippocampus (C), and left ventricle (D). Data are
expressed as mean fold change  SEM compared to vehicle-treated animals
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Expression of p38 mRNA levels were also statistically different
between groups subjected to my E2-deprivation paradigm (Fig. 23). In the
hypothalamus (Fig. 23A) p38 expression was significantly increased 4 and 8
weeks post-OVX, with no significant effect of E2 treatment. In the dorsal
hippocampus a significant main effect of time, but not treatment was detected
and pairwise comparisons did not reveal statistically significant changes
between groups (Fig. 23B). A significant interaction of treatment and time
post-OVX was detected in the ventral hippocampus (Table 3), where E2
treatment significantly reduced p38 mRNA at the 12-week time point (Fig.
23C). There were no differences between groups in p38 mRNA expression in
the heart (Fig. 23D).
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Figure 23. Effects of age and E2 treatment on p38 mRNA expression. P38
mRNA was measured using RT-qPCR in the hypothalamus (A), dorsal
hippocampus (B), ventral hippocampus (C), and left ventricle (D). Data are
expressed as mean fold change  SEM compared to vehicle-treated animals
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ERK AND P38 ACTIVATION ARE DIFFERENTIALLY REGULATED BY ERα
AND ERβ
The differential effects of ERβ and ERα on MAPKs signaling have been
previously reported in different experimental systems, and I detected both
forms of the receptor in my samples [178, 179]. Therefore, in order to
determine the contribution of each estrogen receptor, I treated a set of 18 mo
Fisher 344 with the ERβ or ERα specific agonists DPN and PPT, 1 week post
OVX to compare with the vehicle or E2 treated animals at the same time
point. In Fig. 24, the ratio of phosphorylated ERK and total ERK was
measured via Western blot in samples from the hypothalamus (A), dorsal
hippocampus (B), ventral hippocampus (C) and heart (D). In the
hypothalamus, E2 treatment 1 week post OVX determined a significant
inhibition of ERK activation, which was replicated in animals treated with the
ERα agonist PPT. The ERβ specific agonist DPN did not significantly alter the
activation of ERK, indicating that in the hypothalamus ERα is the main
mediator of the inhibition of ERK activity. In the dorsal hippocampus E2 was
found to inhibit ERK activation 1 week post OVX, and in panel B of Fig. 24
ERβ and ERα specific agonists show a similar effect. All treatments
significantly inhibited ERK activation compared to vehicle treated animals. No
significant changes in ERK activation were detected in the ventral
hippocampus when animals were treated with E2, DPN or PPT. Although a
trend to a decrease was observed in the E2 treated animals. In the heart, E2
treatment does not alter ERK activation 1 week post OVX and neither do DPN
PPT (see Fig. 24 D).
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Figure 24. ERK activation is differentially regulated by ER isoform specific
agonists. Ratio of phospho:totalERK in the hypothalamus (A), dorsal
hippocampus (B), ventral hippocampus (C), heart (D) of 18 months old rats
treated with V, E2, DPN (ERβ agonist) or PPT ( ERα agonist) 1 week post
OVX. Total and phosphorylated ERK were measured via Western blot; ratio of
the two is represented here. Fold change compared to vehicle-treated
animals. An * indicates statistically significant difference between groups
using one-way ANOVA p<0.05 (n=4/6 animals per group)
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The ratio pf phosphorylated p38 and total p38 was calculated following
Western blot analysis in the hypothalamus (A), dorsal hippocampus (B),
ventral hippocampus (C) and heart (D) as shown in Fig. 25. In the
hypothalamus PPT treatment alone significantly increased p38 activation 5
fold, while in E2 and DPN treated animals levels were similar to the vehicle
group. The fact that E2 alone does not increase p38 activation while PPT
does might be reflective of E2 binding to heterodimers. The other regions did
not show any statistically significant effect of DPN or PPT on p38 activation.
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Figure 25. p38 activation is differentially regulated by ER isoform specific
agonists. Ratio of phospho:total-p38 in the hypothalamus (A), dorsal
hippocampus (B), ventral hippocampus (C), heart (D) of 18 months old rats
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Consistent with what has been observed throughout this study, ERK
activity was more sensitive to my animal paradigm than p38. Interestingly, I
found that the ER isoforms differentially alter kinase activity. Overall I found
that in the hypothalamus ERα plays a more important role on MAPKs
regulation. I have shown that E2 treatment leads to inhibition of ERK likely by
activating ERα. Furthermore, stimulation of ERα but not ERβ activates p38.
However, in the dorsal hippocampus both receptor specific agonists had the
same effects as E2.
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Table 3. F-values and p values from two factor ANOVA analysis.
Hypothalamus
Interaction Treatment X Time
Main Effect of Treatment
ERKmRNA
No
No
ERK protein
No
No
phosphoERK
No
Yes F (1,39)= 18.226 p<0.001
Ratio
No
Yes F (1,44)= 15.670 p<0.001

Main effect of Time
Yes F(3, 37)= 3.320, p<0.001
No
No
No

p38mRNA
p38 protein
phospho p38
Ratio

No
No
No
No

Yes F(3, 35)= 6.474, p= 0.001
Yes F( 3,36)= 11.346, p<0.001
No
Yes F (3,36)= 3.821, p=0.018

Main Effect of Treatment
No
No
No
No

Main effect of Time
Yes F (3,32)= 4.105, p=0.014
No
No
No

No
No
No
No

Yes F(3, 33)= 4.214, p= 0.013
No
Yes F(3, 37)= 6.586, p= 0.001
Yes F(3, 37)= 5.653, p= 0.003

Ventral Hippocampus
Interaction Treatment X Time
ERKmRNA
No
ERK protein
Yes F (3, 31)= 2.915, p= 0.050
phosphoERK
Yes F (3, 34)= 3.205, p= 0.035
Ratio
Yes F (3, 35)= 3.177, p= 0.037

Main Effect of Treatment
No
Yes F (1, 31)= 6.294 , p= 0.018
Yes F (1, 34)= 4.806 , p= 0.035
No

Main effect of Time
No
Yes F (3, 31)= 12.942, p<0.001
Yes F (3, 34)= 3.955, p= 0.016
No

p38mRNA
p38 protein
phospho p38
Ratio

Yes F (3, 37)= 6.621, p= 0.003
Yes F (3, 33)= 4.624, p= 0.008
No
Yes F (3, 32)= 3.727, p= 0.021

Yes F (1, 37)= 7.783, p= 0.008
No
No
No

Yes F (3, 37)= 6.493, p= 0.001
Yes F (3, 33)= 3.583 p= 0.024
Yes F (3, 34)= 4.822, p= 0.007
Yes F (3, 32)= 6.713, p= 0.001

ERKmRNA
ERK protein
phosphoERK
Ratio

Interaction Treatment X Time
Yes F (3, 35)= 3.385, p= 0.029
Yes F (3, 58)= 4.430, p= 0.007
Yes F (3, 59)= 5.227, p= 0.003
No

Main Effect of Treatment
No
No
Yes F (1, 59)= 4.893, p= 0.031
No

Main effect of Time
Yes F (3, 35)= 8.502, p<0.001
Yes F (3, 58)= 6.806, p=0.001
Yes F (3, 59)= 20.089, p<0.001
Yes F (3, 60)= 14.834, p<0.001

p38mRNA
p38 protein
phospho p38
Ratio

No
No
Yes F (3, 44)= 3.502, p= 0.023
No

No
No
No
No

Yes F(3, 35)= 2.385, p<0.001
No
No
Yes F(3, 51)= 5.299, p= 0.003

No
No
No
Yes F (3,33)= 3.558, p=0.025

Dorsal Hippocampus
Interaction Treatment X Time
ERKmRNA
No
ERK protein
No
phosphoERK
Yes F (3,39)= 4.012, p=0.014
Ratio
No
p38mRNA
p38 protein
phospho p38
Ratio

No
No
No
No

Heart

91

DISCUSSION
MAPKs are central components of second messenger signaling
pathways and are ubiquitously expressed in all cell types, therefore the
functional implications for these findings are widespread. Here, I report the
novel findings that E2 treatment differentially affects ERK and p38 activation,
as well as total protein and mRNA expression, in the brain and the heart
dependent on age and length of time following E2 deprivation (i.e.
OVX/menopause). Importantly, length of E2 deprivation was a critical factor in
every parameter analyzed. For example, ERK and p38 were significantly less
active 4 or more weeks following OVX regardless of treatment in the heart,
possibly reflecting an age-related change. Age has been shown to both
increase and decrease MAPKs activation, depending on tissue analyzed, sex,
age and species of the animal model, as well as experimental design [106,
107, 180, 181]. For instance, Li et al. hypothesized that p38, a key regulator
of pro-inflammatory cytokine biosynthesis, would be activated by the low
grade inflammation that is associated with the aging process. They observed
increased levels of inflammatory markers accompanied by doubling in p38
activation in the lung and whole brain homogenate of old (20 mo.) compared
to young (2 mo.) C57BL/6J mice [106]. Similarly, p38 expression and activity
was increased by 2.5 fold in the brain of 26 mo. compared to 2 mo. Fisher 344
rats [107]. These findings align with my results in the hypothalamus where
p38 had a 2.5 fold increase 12 weeks post-OVX, regardless of treatment.
However, these results were brain region specific, as I did not observe agerelated changes for phospho-p38 in other brain regions analyzed.
Perhaps most intriguing was the observation that E2-induced changes
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in activated ERK and p38 were prolonged, given that the last dose of E2 was
administered 24 hours before euthanasia. The prevailing view is that the nongenomic actions of E2 occur within minutes and the effects on MAPK
phosphorylation are transitory. Indeed, this has been observed repeatedly in
vitro, however accumulating evidence suggests that the in vivo regulation of
MAPKs is more complex [110, 114, 169, 182-187]. One possibility is that E2,
acting through classical genomic pathways, altered cellular components
required for maintaining balance between active and inactive MAPKs. For
example, crosstalk between phosphorylation and ubiquitination pathways can
exert long-term changes in cellular processes through multiple feedback loops
that ultimately impact apoptosis and cell proliferation [188]. Moreover, I along
with others have shown that E2 can regulate microRNAs in the brain and the
heart, and some of these miRNAs could target components of MAPK
signaling pathways [179, 189-192] providing a putative mechanism for
sustained activation of these kinases. These results were further corroborated
in a 2013 study which showed E2 could regulate long-term activation of
MAPKs by altering expression of microRNAs that silence upstream inhibitors
of ERK activation [192]. The findings herein combined with other published
studies suggest that E2 can exert prolonged changes in MAPKs activation
that cannot be explained by the acute non-genomic actions of E2 alone.
The significant interactions observed between the two factors of time
and E2 treatment for ERK, but not p38, in nearly every brain region and in the
heart could have important functional ramifications for understanding the
physiological consequences of ET in postmenopausal women. Specifically,
the timing of E2 treatment would not be expected to impact p38 signaling in
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these tissues, despite the fact p38 activity was independently altered by E2
and age. Conversely, activated ERK was mainly decreased following E2
treatment and the timing of E2 treatment dictated the magnitude of decline.
Activation of ERK induces downstream signaling pathways that mediate both
neuro- and cardioprotection. For instance, the formation of dendritic spines
was increased by E2 treatment through ERK-mediated mTOR (mammalian
target of rapamycin) and this E2-induced synaptic plasticity is a key
mechanism underlying memory consolidation and storage [193]. Similarly,
activated ERK mediates cardioprotective pathways in the heart and phosphoERK is increased by E2 in young adult rat cardiomyocytes [110, 170, 194196]. The E2-induced decrease of activated ERK in the brain and heart
following longer periods post-OVX reveal a putative mechanism for memory
decline and reduced cardioprotection following ET in late postmenopausal
women.
Increased estrogen receptor-mediated gene transcription is the most
likely explanation for my observed increases in total ERK and p38 protein
levels. Indeed, I found that the mRNA levels of both kinases were significantly
altered by E2 treatment and length of deprivation in the brain and heart.
Sequence analysis of the ERK and p38 gene promoters revealed an
abundance of binding sites for several transcription factors such as NF-kB
and GATA families as well as multiple estrogen response elements (ERE)
[197]. The canonical actions of ERs are through direct ERE binding, however
ERs can also regulate transcription by tethering to other transcription factors,
such as members of the Jun and Fos families acting at AP-1 sites (activator
protein-1) [198]. Notably, there are 28 and 34 identified AP-1 sites within 2000
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bp upstream of the p38 and ERK translation start sites, respectively. These
data demonstrate that there are multiple mechanisms for E2 to regulate ERK
and p38 transcription directly at the level of the gene promoter.
In the last decade, sophisticated genomic and proteomic tools have
allowed for the quantitative molecular analysis of complex biological samples.
These experiments revealed low correlations between mRNA and protein
levels in many samples [199]. Similarly, changes in ERK and p38 protein
levels did not tightly correlate with their altered mRNA levels in my paradigm.
This suggests that age and/or E2 treatment can regulate compensatory
factors that affect protein translation or stability. For example I observed a 3 to
5- fold increase of ERK mRNA following prolonged E2 deprivation in the
hypothalamus, yet total ERK protein was unchanged. This could be partly
explained by the semi-quantitative nature of the techniques (i.e. Western blot).
Alternatively, this observation could be due to increased mRNA turnover or
translational inhibition. Several mechanisms of post transcriptional regulation
of mRNA have been described and microRNAs are interesting example of
regulatory molecules that can repress target mRNA translation [200]. My
recent work demonstrated that microRNA expression is differentially regulated
by prolonged E2 deprivation and subsequent E2 treatment using this same
animal treatment paradigm in aged rats [179, 190]. In line with the current
findings, several of those E2-regulated microRNAs have the potential to inhibit
p38 and ERK mRNA translation, resulting in decreased protein levels. I also
identified a subset of microRNAs that are differentially regulated by E2 in
young (3 mo.) vs. old (18 mo.) rats using a microRNA microarray platform
[190]. Bioinformatics pathway analyses revealed that the MAPK pathway was
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predicted as the most represented cellular pathway targeted by the
microRNAs I identified as E2 regulated [190]. Regulation of microRNAs is just
one possible explanation for the discrepancies seen between mRNA and
protein levels in complex biological samples.
I also sought to determine which ERs might be mediating the effects on
MAPKs activity in my animal paradigm. My group has recently demonstrated
that in animals subject to my experimental paradigm both ERα and ERβ are
expressed in the brain regions in analysis and in the heart throughout all time
points and treatments [178, 201]. Furthermore I have analyzed the expression
of ERβ2, a splice variant of ERβ, which is a constitutively active form of the
receptor, and found that it was regulated by estrogen deprivation following
OVX as well as E2 [178]. Here I have determined that 1 week post OVX E2
significantly inhibits ERK activation, likely via ERα whose activation also
significantly inhibited ERK activation. Similarly p38 activation was also
activated by E2 treatment and ERα agonist PPT in the hypothalamus, while
ERβ agonist DPN had no effect. In the dorsal hippocampus however both
ERα and ERβ agonists inhibited ERK activation as did E2. Isoform specific
effects of ERs are known, however this is the first in vivo analysis of MAPKs
regulation in the brain and heart.
Despite the understanding of the importance of the time of initiation of
ET in women for neuroprotection and cardioprotection gained from clinical
studies, clear mechanistic insight is still lacking. I designed my study to model
a main tenet of the timing hypothesis, as based on clinical observations [59,
202, 203]. One limitation is that rodent reproductive senescence is not
comparable to the menopausal transition in women [204, 205]. However, the
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surgically-induced menopause model used in rodents is the most accurate
method to determine the length of time following total ovarian hormone
depletion, and surgically-induced menopause is clinically relevant for some
women. I have also demonstrated previously that 18 months of age is a
physiologically relevant comparison to human in this strain of rat (Fisher 344),
although Sprague Dawley rats demonstrate much earlier reproductive
senescence [178]. The concepts referred as “window of opportunity” or “timing
hypothesis” emerged from clinical studies that found that age of ET initiation
determined the successful outcome of the study. Indeed estrogens reduced
risk of cognitive decline and dementia when administered to women in early
stage of menopause [56]. Postmenopausal women receiving ET in a 2012
Danish study also had significantly reduced risk of mortality and heart failure,
without an increased risk of breast cancer or stroke [57]. The WHI ET followup showed that women 50-59 of age had statistically significant reduction in
coronary heart disease (Hazard Ratio HR of 0.59), myocardial infarction (HR
0.54) and overall mortality (0.73) [58]. These are only a few examples of how
cognitive and cardiovascular health of menopausal women can be improved if
ET is started at the right time (i.e. in early menopause). My data highlights
MAPKs as a possible focus of further analysis, as these kinases are critical
regulators of cell signaling pathways.
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CHAPTER V
QUANTITATIVE MASS SPECTROMETRY FOR IN VIVO ANALYSIS OF
PHOSPHORYLATED ERβ
INTRODUCTION
Phosphorylation of ERβ significantly alters its function as a
transcription factor as shown in Chapter III [206]. ERβ can be phosphorylated
in its N-terminal domain at two sites, S87 and S105. This was shown first by
mutating mouse ERβ in the homologous Serines into Alanines and performing
in vitro phosphorylation with radioactive p32ATP [128]. The Mutant ERβ failed
to incorporate p32ATP, indicating that S87 and S105 are phosphorylated at
those sites. Separate groups have found that ERβ can be phosphorylated in
vitro by the MAPKs ERK1, ERK2, p38 but not Src or PKA [81, 128]. Later,
phosphorylation of purified human ERβ at S105 was verified following in vitro
phosphorylation using mass spectrometry (MS) [81]. I have extended these
findings by demonstrating detection of phosphorylated ERβ, in vivo, in the
brain and heart of aged rats using PhosTagTM immunoblotting (Chapter III).
While this technique allowed for detection of phosphorylated forms of ERβ,
the site or sites at which the phosphates are attached cannot be determined
with this technique. Importantly, site specific modifications altered ERβ
function, as shown in Chapter III, therefore the identification of distinct
phosphorylated residues in vivo is a critical next step.

Phosphorylation of ERβ in vivo was also detected using antibodies
directed against the phosphoS105ERβ peptide through immunohistochemical
staining of human breast tissue samples [81]. While this is a positive
indication of the presence of phosphoS105ERβ in human breast, antibody
based assays are often misleading when studying ERβ. Indeed a thorough
analysis of nine antibodies available revealed that while some do recognize
ERβ used in certain techniques, most lack specificity or only work correctly in
a specific application [207]. The lack of reliable tools for investigating ERβ in
vivo is a recurring theme in the field and most experts attribute this to the
partially unfolded state of the N-terminal domain of ERβ [208-211]. The
dynamic structural behavior of ERβ gives it the ability to rapidly interact with
different coregulatory proteins, localize to different intracellular organelles and
transition on and off the DNA quickly, overall determining its functional
heterogeneity that makes it an important target of investigation.
The activity of the MAPKs p38 and ERK, the kinases that have been
shown to phosphorylate ERβ, is sensitive to aging and estrogen treatment.
Indeed the findings described in Chapter IV demonstrated that the length of
estrogen deprivation prior to estrogen treatment altered MAPKs activation in
the brain and heart of aged rats. Therefore, it is likely that levels of
phosphorylated ERβ are different in the tissues of rats that underwent the
estrogen deprivation paradigm. ERβ mediates important neuroprotective and
cardioprotective effects of estrogens and its phosphorylation has functional
consequences as shown in Chapter III. Therefore it is pivotal to detect and
compare levels of phosphorylated ERβ in brain and hearts.
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The experimental approach I chose was to use Multiple Reaction
Monitoring (MRM) (also referred to as Selected Reaction Monitoring or SRM);
a mass spectrometry based method that allows for detection and
quantification of low abundance peptides in complex samples. Briefly, during
an MRM experiment a predefined peptide of interest is detected using a Triple
Quadrupole mass spectrometer. By mixing a known amount of a peptide
identical to the target peptide but incorporating heavy isotopes, the amount of
unknown peptide can be readily quantified. Further, using heavy labelled
peptides that are phosphorylated at the site of interest allows for the
quantification of the phosphorylated form of the peptide.
There are multiple steps that must be performed in order to create the
MRM including 1) analysis of the protein sequence of interest to obtain a
theoretical digestion profile, 2) empirical testing of digestion profile with a
purified protein, 3) optimization of instrumentation parameters using
synthetically developed peptide fragments, 4) development of the MRM using
increased sample complexity, 5) isolation of in vivo experimental protein
samples and mass spectrometry analysis. Fig. 26 is a schematic
representation of the experiments described in this Chapter and details the
preliminary steps necessary for MRM method design.
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Size

1

Analyze Protein
Sequence

Theoretical digestion
profile

Target Peptide
Theoretical Missed Cleavage

ERβ-His plasmid

2

Perform Empirical
Digestion

2a) Synthetize
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Transform and screen
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Large scale production
ERβ-His purification

In gel and in solution
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digestion

MALDI-TOF

Detection of target
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Verification of
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3
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Evaluate ionization and
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Chromatography

4

Develop LC-MRM
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Pick optimal
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5
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experimental
samples

Digest tissue protein spiked
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experiment -biological and
experimental replicates

Data analysis (Skyline)

Figure 26. Outline of the experiments described in this Chapter.
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MRM experiments are usually performed using Liquid Chromatography
(LC) coupled to Triple Quadrupole mass spectrometers. These types of
instruments are designed to follow the work flow diagram depicted in Fig. 27.
First, samples are injected in the chromatography column; typically a C18
column which is made of an 18 carbon chain bound on a silica substrate.
Peptides adsorb to the column and by gradually increasing the amount of
polar solvent in the mobile phase they elute separately according to their
biochemical characteristics. This step reduces the complexity of the sample
prior to injection in the mass spectrometer. Second, ionization of the peptides
is achieved by applying a high voltage to the peptides to create an aerosol
with the electrospray ionization (ESI) probe. ESI does not fragment the
peptides and can create multiply charged ions (z>1). Third, the ionized
peptides move into the first quadrupole (Q1) and are analyzed by mass.
Fourth, in the second quadrupole (Q2) the ions are collided with high pressure
gas (argon) inducing dissociation of the ions in a process called collision
induced dissociation (CID). Each ionized peptide that entered Q1 (precursor
ion) will then be fragmented in Q2 into product ions that will be detected by
Q3, which also analyzes each fragment by mass. The m/z values of precursor
ions and product ions that will be generated after CID can be predicted based
on the sequence for the peptide of interest. The collision induces breakage of
the amide bond and loss of amino acids at the N- and C- termini of the
peptide, and the resulting ions are called y- and b- ions. In MRM, the
precursor ion of interest is selected in Q1 and the product ions of interest are
monitored in Q3. MRM is an example of a targeted mass spectrometry
approach, as this method only detects a selected peptide of interest. The
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AQUA (absolute quantification) method was developed to directly quantify
peptides using MRM [212]. Briefly, synthetic peptides of the same sequence
as the peptide of interest are synthetized using a heavy labelled amino acid,
shifting their mass by a known amount. These heavy peptides are used as
internal standards and spiked with the unknown sample containing the light
peptide of interest. The heavy peptides have the same retention time,
ionization and fragmentation characteristics, but have a shift in mass which
allows for comparison of intensity of endogenous (light) and heavy peptides.

LC/ESI

Q1
Precursor ion
isolation

Q2
Collision
Induced
Dissociation

Q3
Fragment
ions
Selection

Detector

Figure 27. Schematic representation of the Triple Quadrupole mass
spectrometer used for MRM.
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RESULTS
1) Analyze ERβ Sequence
The first step in determining whether MRM is a feasible approach to
detect and quantify ERβ phosphorylation is to analyze its sequence. Indeed it
is necessary to enzymatically cleave proteins in smaller peptides that can be
detected by Triple Quadrupole mass spectrometers for MRM experiments.
Protein digestion is a common procedure in proteomics and several
proteolytic enzymes are available commercially. Each protease has very
specific cleavage sites; empirical digestion of the protein of interest can be
tested using bioinformatics tools such as Expasy Peptide Cutter [213]. The
size of the peptide of interest is also an important consideration for MRM
experiments. A maximum length of 25 amino acids is indicated for a few main
reasons. First, mass of larger peptides is over the limit of detection of Triple
Quadrupole mass spectrometers. Furthermore long peptides are typically
unsuitable for synthesis. Finally amino acid side chains can potentially be
modified during ionization and dissociation in the mass spectrometer, and
longer sequences have more potential for modifications which would
complicate the analysis. Another crucial factor when deciding which enzyme
to use for digestion is the uniqueness of the sequence of the peptide of
interest. Therefore, to avoid false positive results, it is essential to scan the
NCBI database to confirm that the target peptide fragment is unique to the
protein of interest. Finally, protease efficiency is high, however some cleavage
sites are more optimal than others, and bioinformaticians have developed
algorithms to predict the likeliness of a “missed cleavage” to occur [214].
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I performed the steps described above using the rERβ sequence
available from Uniprot (accession number Q62986). The goal was to identify a
protease that would digest ERβ containing the desired S87 and S105 sites in
peptide fragments that met the optimal criteria for MRM. I first used Expasy
peptide cutter to obtain ERβ digestion profiles for eight common proteases.
Figure 28 shows the results of the theoretical digestion. The right column lists
the cleavage sites for each proteases and I focused on proteases that cleaved
the protein at residues close to S87 and S105. I calculated the size of the
peptides containing S87 and S105 and evaluated my options. Arg-C, Asp-N,
low-specificity-Chymotrypsin and Proteinase K were not feasible enzymes as
they would not yield ERβ peptides I could use for MRM. Cleavage of ERβ with
Lys-C or Lys-N yielded S87 and S105 containing fragments of 100 or 21
amino acid length each. On average MRM experiments use peptide of 10
amino acids, however it is possible to use peptides up to 25 amino acid long.
Chymotrypsin digestion of ERβ generated a 43 amino acid peptide with S87
and an 8 amino acid peptide with S105. Trypsin digestion resulted in a 33
amino acid peptide encompassing S87 and a 7 amino acid peptide
encompassing S105. This preliminary analysis revealed that none of the
available enzymes would digest ERβ so that S87 would be contained in a
fragment of the length required for MRM. This depends on the protein in the
region surrounding S87, and makes the study of phosphorylation of S87 with
the MRM approach unfeasible. However, as shown in chapter III,
phosphorylation of S87 leads to more modest changes in ERβ function
compared to S105, suggesting that phosphorylation at that site is less
important in vivo. Furthermore, phosphorylated S105-ER was detected in
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breast tissue samples and inhibited breast cancer cells invasiveness and
migration [81]. Together, these data suggested that S105 was the best target
for additional proteomics analysis and both high-specificity Chymostrypsin
and Trypsin are feasible proteolytic enzymes (Fig. 28). Trypsin is the universal
enzyme used in proteomics because it is readily available, economical, and
several validated protocols are published. Furthermore, large data sets using
mass spectrometry are available online allowing for preliminary identification
about whether a protein of interest has been detected using similar
techniques and most of the data collected used Trypsin digestion. Analysis of
the available data sets showed that human and rat sequences are identical in
the N-terminal region containing S105. Also, in vitro phosphorylated human
ERβ at S105 was detected following tryptic digestion [81]. In that study, an
Orbitrap mass spectrometer was used to detect the phosphorylated form of
ER, but this was a positive indication that empirical tryptic digestion of ERβ
would result in that peptide fragment (i.e. it is not a missed cleavage), and that
the peptide can be ionized and detected using a mass spectrometer.
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Fig. 28 Theoretical digestion of rERβ with 8 available enzymes.
(PeptideCutter, Expasy.org)
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Next, analysis of the predicted ERβ tryptic digestion was done using
PeptideMass, an Expasy bioinformatics tool, to analyze the mass of the
peptide of interest. Common to most digestion protocols is the treatment of
the samples with Dithiothreitol (DTT), a reducing agent, following by
Iodacetamide, an alkylating reagent. The first step is necessary to convert
cysteine side chains from disulfide bonds into free cysteine side chains.
Iodacetamide treatment then alkylates the free sulfhydryl side chains adding a
carbamidomethyl group (CAM), ensuring that no free sulfhydryl groups
reform. These steps are necessary to allow for Trypsin’s full access to all
cleavage sites and results in a 57.021 Da increase in mass to all cysteine
containing peptides. Fig. 29, shows that following tryptic digestion of ERβ
S105 results in a 7 amino acid peptide: SPWCEAR. The mass of the peptide
is 905.3934 Da following CAM modification on the cysteine, which is ideal for
detection using a Triple Quadrupole. This same peptide was detected, with
the CAM modification, in the Lam et al. study, indicating successful digestion
and modification [81].
While commercially available Trypsin is highly efficient, missed
cleavage can occur. As explained earlier, missed cleavage probability can be
predicted by algorithms created after analysis of all peptides that contain a
missed cleavage in a large data repository (PeptideAtlas). Therefore, I tested
the probability of missed cleavage upstream and downstream of the
SPWCEAR sequence using the missed cleavage predictor program
developed by King’s University [214], and the results are shown in Fig. 30.
The right column indicates a score from 0-1, with the missed cleavages
resulting in a higher score. Both N- and C- terminal cleavage sites have a
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relatively low score, a positive indication that digestion with trypsin will
successfully yield the target peptide containing S105.
Figure 29. Analysis of ERβ tryptic peptides (PeptideMass, Expasy.org).

109

Figure 30. Analysis of Tryptic digestion of ERβ for potential missed cleavage
sites. (Missed Cleavage Predictor described in [214]).
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2) Empirical ERβ digestion
2a) Obtain recombinant ERβ
While theoretical digestion analyses are the basis of all targeted
mass spectrometry experiments, empirical digestion has to be
performed before moving on with the synthesis of the heavy labelled
peptides that will be used for the MRM. In collaboration with Mengjie
Zhang, Research Specialist in Dr. Pieter de Tombe’s laboratory, I used
an in vitro bacterial expression system to obtain large amounts of
purified ER [215]. First, the rERβ sequence was cloned into the
pEXP5-CT/TOPO expression vector, so that a 6histidine tag is cotranslated at the C-terminus of ERβ. In this vector, the T7 RNA
polymerase necessary for translation of ERβ-His is under regulation of
a Lac promoter. Therefore, induction with the lactose metabolite IPTG
(Isopropyl β-D-1-thiogalactopyranoside) was required to obtain ERβHis6. BL21 DE3 competent cells were transformed with the ERβ-His6
plasmid and plated overnight. Five colonies were picked and grown in
liquid culture before being split into 2 aliquots. One of the aliquots (B)
was induced with IPTG, the other (A), was not induced and served as
the control. Following overnight incubation, cells were lysed and protein
isolated. Screening of the colonies that most efficiently produced ERβHis6 after induction was done by analyzing Coomassie stained gels
containing the protein. As seen in Fig. 31, IPTG induced samples
showed a strong band at the expected 50KDa mass (see arrow), which
was not present in the in control (IPTG-free = A) samples. Clone 5 had
the highest intensity band, indicating a stronger induction of translation
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of the ERβ-His6 protein, and was chosen for large-scale protein
production.

Figure 31. Screening of 5 clones following protein induction with IPTG.
Protein visualized with Coomassie staining. Arrows indicate induced protein of
the expected molecular weight of ERβ-His6.
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Next, protein was isolated from 4 liters of bacterial culture and
purified using a nickel affinity column that binds to the His6-tag of the
ERβ-His6 protein. After binding to the column and a wash cycle, elution
buffer containing Imidazole (which competes for binding to the nickel
column) was added and eluted protein fractions were collected. The
example in Fig. 32 shows protein fractions 12-21; as the arrow
indicates, fraction 19 contained the target ERβ-His6 protein. Western
blot analysis of the protein confirmed that both ERβ and the His-tag6
were correctly translated (Fig. 33).

Figure 32. Screening of eluted fractions 12-21 after IMAC. Protein visualized
with Coomassie staining. Arrow indicates induced protein of the expected
molecular weight of ERβ-His.
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Figure 33. Representative Western blot staining of protein from the eluted
fractions containing putative ER based on Coomassie stain. Membrane was
incubated with primary antibody targeting N-terminal ER confirming
expression at expected molecular weight.
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2b) Recombinant ERβ digestion
Confirmation of the theoretical and previously published results were
then accomplished by tryptic digestion of the recombinant ERβ-His6 protein
(obtained by pooling and concentrating IMAC fractions) [81]. First, ERβ-His6
protein was run on a SDS-PAGE gel and the gel band containing ERβ was
excised, as well as a portion of the gel void of protein to be used as a
negative control (see arrows in Fig. 34). Second, a standard in gel Trypsin
digestion protocol was used to clean, reduce and alkylate the protein prior to
an overnight incubation with Trypsin (see Methods for details). Digested
peptides were then washed out from the gel and concentrated to a smaller
volume using a SpeedVac centrifuge. The peptides were then mixed with a
matrix (α-Cyano-4-hydroxycinnamic acid, CHCA) which facilities ionization in
MALDI-TOF mass spectrometry (Matrix Assisted Laser Desorption ionizationTime of Flight). Briefly, the samples mixed with the matrix are irradiated with
a laser, causing the matrix together with the peptides to ionize and vaporize.
Using an Axima-CFR Plus MALDI-TOF MS system in “reflecton mode”, the
charged ions are reflected using an electrical field and are accelerated in a
vacuum. The time of flight to the detector is dependent on the mass of the
peptides. Therefore, using calibrants of known mass and measuring their
TOF, it is possible to calculate the mass of the sample peptides. I used a 7point calibration curve and recalibrated the instrument between each sample.
Repetitively, I was able to detect several expected tryptic peptides or ERβ,
including the peptide of interest containing S105. Fig. 35 is an example of a
spectrum acquired as described above. The y-axis shows the normalized %
intensity of the ions and the x-axis shows the mass to charge ratio (m/z).
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Importantly, only charged ions can be analyzed and detected by the mass
spectrometer, hence the need of the matrix and laser bombardment. The red
and blue traces represent two separate duplicates of the in-gel digestion
products of ERβ-His6 protein. The numbers indicate m/z of ions that were
automatically detected by having high intensity. Indeed several of those, and
others at lower m/z not showed in this example, match the mass of tryptic
products of ERβ. Importantly a peak of 905.4 m/z is present in this example
and others; this matches the mass of a singly charged SPWCEAR peptide
containing S105. Ions are usually only singly charged in MALDI because it is
a milder form of ionization compared to others such as ESI, which will be
introduced in the next section.
The empirical digestion of ERβ-His6 protein with Trypsin successfully
led to the peptide of interest containing S105. This process confirmed the
theoretical results and the empirical results with the human form of ERβ [81].
These steps were necessary to evaluate whether the MRM approach would
be feasible and the synthesis of target peptide would be necessary.
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Figure 34. ERβ-His6 protein was run on a SDS-PAGE gel in duplicate and
stained with Coomassie stain. Gel bands containing the protein of interest and
a negative control were excised (See arrows).
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Figure 35. Representative MALDI-TOF spectrum of gel digestion products of
ERβ-His6.
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3) Use target ERβ peptides to develop the MRM
The target SPWCEAR peptides required for development and
validation of AQUA-MRM were synthesized by ThermoFisher Scientific
with heavy Arginine which is 10 Da heavier due to the presence of C13
and N15 isotopes. Phosphorylated peptides were also synthetized in
the light and heavy version (Fig. 36).
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1
2
3
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KS35084.2 pERB-light
KS35084.3 ERB-Heavy
KS35084.4 pERB-Heavy

12/1/2015 5:59
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50% ACN / 0,1%TFA
50% ACN / 0,1%TFA
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[H]
[H]
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[OH]
[OH]
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1.9
3.1
1.5
1.2

Figure 36. Characteristics of the four SPWCEAR peptides purchased.
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4.7
7.7
3.7
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QC

passed
passed
passed
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To develop a reliable MRM method, each peptide has to be tested for
both its ionization and fragmentation characteristic. After electrospray the
peptides can be multiply charged and the most prevalent ion form needs to be
selected in Q1. Then the ion has to go through CID and the full spectrum of
the product ions scanned. From all the product ions that are generated after
dissociation, the most prevalent will be selected in Q3 in the MRM method.
The predicted y- and b- product ions of each peptide, can be obtained
using bioinformatics tool such as MS-product, a program developed by the
University of California. Fig. 37 shows the precursors and products m/z for the
light and heavy SPWCEAR peptides. Note that the heavy peptide is 10m/z
heavier that the light form in both the precursor and product ions that contain
the heavy arginine.
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Figure 37. Predicted precursor and product ions for the light and heavy
unphosphorylated SPWCEAR peptide.
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A full scan analysis of each peptide, with no dissociation induced,
shows which charged species are generated for each peptide. The spectrum
in Fig.38 was collected from a directly infused short unphosphorylated light
peptide. As indicated by the arrows, both the 1+ and 2+ species are
generated. Because of the double charge the m/z of the 2+ species is equal to
1/2 of the ion’s mass. The most prevalent species was the 2+ ion, and was
selected in Q1 for the MRM experiment. For all four peptides the doubly
charged ion was the most prevalent following electrospray ionization,
therefore the 2+ ions was selected for fragmentation.
The subsequent step used Q3 to detect the full spectrum of product
ions derived from dissociation of the 2+ precursor ions. Representative
spectra of the light and heavy unphosphorylated peptides are shown in Fig.
39. As indicated by the arrows, several of the predicted product ions were
detected.
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Figure 38. Spectrum for the SPWCEAR peptide. Arrows indicate the 1+ and
2+ species.
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28

Figure 39. Spectra detected in Q3 showing product ions of the 424.66
(above) and 429.63 (below) precursor ions, the 2+ ion of the light
unphosphorylated light (above) and heavy (below) peptides. Arrows indicate
the m/z values that match the predicted products (for a list see Fig. 37).

124

Collision energy (CE) applied in Q2 to induce ion dissociation must be
optimized in order to determine that all of the precursor ions are dissociated
into product ions. Optimal CE can be theoretically calculated, but then must
be empirically verified. My results showed that the phosphorylated peptides
required slightly higher energy for a complete dissociation, due to their larger
size because of the 79Da addition of the phosphate, however efficient
dissociation was obtained with similar CE.
In AQUA-MRM experiments, confident detection and quantification is
best achieved through the use of four transitions (precursor and product ions
pairs). In addition, the MRM method must be designed to target the CAM
modified peptides to mimic the true MRM experiment, in which the peptides
go through the trypsin digestion protocol. The four transitions that were highly
reproducible and were chosen for the final MRM design are listed in Fig. 40.
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Protein Name
ERBETA
light
ERBETA
unphosphorylated
ERBETA
peptide
ERBETA
ERBETA
heavy
ERBETA
unphosphorylated
ERBETA
peptide
ERBETA
ERBETA
light
ERBETA
phosphorylated
ERBETA
peptide
ERBETA
ERBETA
heavy
ERBETA
phosphorylated
ERBETA
peptide
ERBETA

Peptide Modified Sequence
SPWC[+57.1]EAR
SPWC[+57.1]EAR
SPWC[+57.1]EAR
SPWC[+57.1]EAR
SPWC[+57.1]EAR
SPWC[+57.1]EAR
SPWC[+57.1]EAR
SPWC[+57.1]EAR
S[+80]PWC[+57.1]EAR
S[+80]PWC[+57.1]EAR
S[+80]PWC[+57.1]EAR
S[+80]PWC[+57.1]EAR
S[+80]PWC[+57.1]EAR
S[+80]PWC[+57.1]EAR
S[+80]PWC[+57.1]EAR
S[+80]PWC[+57.1]EAR

Ion Formula
C38H56N12O12S
C38H56N12O12S
C38H56N12O12S
C38H56N12O12S
C38H56N12O12S
C38H56N12O12S
C38H56N12O12S
C38H56N12O12S
C38H57N12O15PS
C38H57N12O15PS
C38H57N12O15PS
C38H57N12O15PS
C38H57N12O15PS
C38H57N12O15PS
C38H57N12O15PS
C38H57N12O15PS

Precursor Mz Precursor Charge Product Mz
Fragment Ion
453.504846
2
721.30862 y5
453.504846
2
535.229307 y4
453.504846
2
375.198659 y3
453.504846
2
246.156066 y2
458.469178
2
731.316889 y5
458.469178
2
545.237576 y4
458.469178
2
385.206928 y3
458.469178
2
256.164335 y2
493.494796
2
721.30862 y5
493.494796
2
535.229307 y4
493.494796
2
375.198659 y3
493.494796
2
246.156066 y2
498.459129
2
731.316889 y5
498.459129
2
545.237576 y4
498.459129
2
385.206928 y3
498.459129
2
256.164335 y2

Figure 40. List of transitions chosen for each target peptide.
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Product Charge Cleavage Aa
1
W
1
C
1
E
1
A
1
W
1
C
1
E
1
A
1
W
1
C
1
E
1
A
1
W
1
C
1
E
1
A

4) Develop LC-MRM method
The initial development of the MRM established the ionization and
fragmentation characteristics of the pure peptides directly injected in the mass
spectrometer by-passing the LC stage. However the final experiment is based
on the ability of the endogenous (light) and exogenously added heavy
peptides to be detected in a complex tissue protein sample following liquid
chromatography. Therefore the LC step of the experiment must be optimized
to determine the elution time of the peptide (i.e. retention time). During a LCMRM method, the instrument cycles through the list of defined transitions for
the duration of the program. Using the Skyline software, created by the
MacCoss lab at the University of Washington, the transitions acquired across
time can be easily viewed. To first test the LC-MRM method, I mixed equal
amounts of each peptide to detect each retention time and tested whether the
transitions observed with the pure peptides were reproducible.
Fig. 41 shows a screenshot of the Skyline software analysis of the LCMRM of the sample mix. On the left panel, each transition is highlighted and
assigned a different color. The chromatogram shows a zoomed in window of
the retention times at which the peptides eluted. The green and light orange
traces represent the unphosphorylated light and heavy peptides which coelute. This result confirmed that the incorporation of the heavy arginine does
not affect retention time. The red traces represent the phosphorylated
peptides which also co-eluted as expected. Each peptide should only elute
once, when the amount of organic solvent in the mobile phase is enough for
the peptide to come off the C18 column and elute.
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Figure 41. Chromatograph of the 4 pure peptides after LC-MRM program. On
the x-axis is retention time, the y-axis is the signal intensity. For color legend
see panel of the left. (Skyline software, MacCoss lab)
Analysis of the intensity of each transition is also possible, and the
prevalence of each product ion should be consistent across replicates. Fig. 42
shows the four transitions monitored for the light unphosphorylated peptide in
separate runs of the peptide alone (on the left) and mixed with the other
peptides. As expected the pattern of each transition is conserved, with the
245.15 product (in orange) being the more intense in both samples.

128

Figure 42. The four transitions monitored for the light unphosphorylated
peptide are shown in a run of the peptide alone (on the left) and mixed will all
other peptides. Retention time and prevalence of each transition are
conserved.
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After optimization of the LC-MRM and establishment of retention time
for each peptide, a standard curve will be prepared using the heavy labeled
peptides. LC-MRM of serial fold dilutions of the unphosphorylated and
phosphorylated heavy peptide will be used for the standard curve. Using the
Xcalibur software, the intensity of the area under the curve of each dilution will
be plotted and fit to a linear curve. The standard curve will be used for
quantification of light (endogenous) peptide in the experimental tissue
samples.
Perform MRM with experimental samples
The LC-MRM method developed above will be used to measure the
ratio of ERβ that is phosphorylated at S105 in the brain and heart of animals
that underwent the estrogen deprivation paradigm. A known amount of the
heavy peptide will be spiked with the tissue sample and, following LC-MRM,
the ratio of the intensity of the endogenous peptide and the added heavy
peptide will be calculated for both the phosphorylated and unphosphorylated
peptides.
Comparison of trypsin digestion of the unphosphorylated and
phosphorylated peptide fragment.
The S105 of interest is directly downstream of the lysine residue
recognized by trypsin in the cleavage site. It is possible that trypsin might not
recognize and, therefore cleave, as efficiently when S105 is phosphorylated.
To evaluate this possibility, I designed a longer peptide with 7 additional
amino acids upstream of S105 (Fig.43). The heavy LYAEPQKSPWCEAR
peptide was synthetized with and without phosphorylation of S105 and then
tested using the same digestion parameters as the shorter peptide. The
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results demonstrated that the heavy phosphorylated peptide was cleaved
after successful digestion with trypsin (Fig. 44, left panel) and the retention
time and most prevalent product ions were similar to the short peptide (Fig.
44, right panel).

Figure 43. The blue box highlights the longer peptide synthesize to study
whether phosphorylation at S105 affects recognition and cleavage by Trypsin.
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Figure 44. The long phosphorylated ERβ peptide (left) is successfully cleaved
and yields transitions that match the short heavy phosphorylated peptide
(right).
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DISCUSSION
In this chapter I have delineated the development of a LC-MRM
experiment that can be used to detect and quantify phosphorylated ERβ.
Optimization of the LC-MRM method is necessary before moving on to
assaying the tissue samples, however I am confident that this experiment is
the best approach to answer the fundamental next questions in this study. I
have already demonstrated that phosphorylated ER is functionally distinct
and alters downstream gene expression compared to the unphosphorylated
form of the receptor (Chap. 3). Moreover, these functional differences are
sensitive to the presence or absence of E2 in the cell, raising the possibility
that ER differentially alters gene expression in postmenopausal women.
Adding to this complexity, the activation of kinases that putatively
phosphorylate ER is differentially altered by age and E2 in the brain and the
heart (Chap. 4), thereby providing a mechanism for differential
phosphorylation of ER with advanced age. The next step is to identify
phosphorylated ER in the brain and heart of aged rats, and quantify changes
in phosphorylation based on age and circulating levels of E2. These data will
allow us to predict whether this functionally important modification is changed
following longer deprivation of estrogen, and potentially is a basis for
explaining the discrepant effects of E2 replacement therapy in
postmenopausal women.
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CHAPTER VI
FINAL DISCUSSION
SUMMARY OF KEY FINDINGS
The aim of this dissertation was to uncover potential molecular
mechanisms of the age related switch of estrogen treatment post menopause.
The project stemmed from the clinical observations brought about from the
Women’s Health Initiative study and the Timing Hypothesis. Important findings
of the WHI were that the neurological and cardiovascular systems specifically
benefit from E2 administration closely in time to the menopausal transition.
The underlying hypothesis of this dissertation was that age and estrogen
deprivation lead to altered kinase activation which could result in altered
phosphorylation of ERβ in the brain and heart.
The first goal was to test whether phosphorylation on ERβ would alter
its activity as a transcription factor in neurons, where estrogens can be
beneficial. Indeed the data presented in Chapter III show that phosphorylation
of ERβ increases its activation of transcription at ERE sites, while abolishing
the ligand independent inhibition of AP-1 sites (see Fig. 45). These represent
two very different modalities of ERβ activity as a transcription factor; the first
requiring direct binding to the DNA at ERE sequences, the second by
interacting with other transcription factors at the AP-1 sequences on the DNA.

+/- E2
ERβERβ

+/- E2
Activate
transcription

P

P

ERβERβ

ERE

ERE

no E2

no E2
ERβERβ

Fos Jun

Increased
transcriptional
activation

P

P

ERβERβ

Inhibit
transcription

AP-1

Fos Jun

No change in
transcription

AP-1

Figure 45. Phosphorylation of ERβ at S105 increases ERE dependent
transcription (above) and abolishes ligand independent inhibition of AP-1 sites
(below).
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The possibility that phosphorylation of ERβ alters its ability to bind to
the DNA at ERE sequences was also tested in Chapter III. The results
showed that ERE binding is not altered when ERβ is phosphorylated in the Nterminal domain which is not known to participate in this interaction. However,
the N-terminal domain (pecifically S87 and S105) is important in mediating
interactions with coregulatory proteins and participates in homo and
heterodimerization.
The Timing Hypothesis relates to the whole organism physiology,
therefore aging and estrogen deprivation need to be investigated in vivo. The
animal paradigm used in this study was designed to investigate the findings of
the WHI study and the Timing Hypothesis. Briefly, aged female rats were
ovariectomized to remove endogenous sources of estrogens. E2 or vehicle
was administered after different lengths of time following the surgery. This
design was chosen due to the clinical studies which showed that the
beneficial effects of E2 depend on how long after menopause women started
ET. The initial hypothesis that MAPKs are differentially activated depending
on age and estrogen deprivation could be tested in this model. Indeed,
measuring the activation of p38 and ERK, members of the MAPK family,
revealed a clear interaction between length of estrogen deprivation and
estrogen treatment. Namely, the length of time between ovariectomy and
beginning of treatment resulted in altered effects of E2 on the activation of
MAPKs. Among the striking results described in Chapter IV, are the clear
brain region-specific and kinase-specific effects detected. Also, the factors of
length of estrogen deprivation and E2 treatment showed significant
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interactions, indicating that different effects of E2 treatment were
detected depending on the time at which it was administered.
Additionally, in Chapter V this dissertation provides the description of a
novel method for detecting and quantifying phosphorylated ERβ in vivo. The
mass spectrometry technique described has been successful for the detection
of lowly expressed proteins but has never been attempted to study ERβ.
Indeed, because of the difficulties experienced in the use of antibody based
assays, the MRM method described offers a reliable alternative.
Taken together, the data presented in this dissertation demonstrate
that alternative regulation of MAPKs signaling in the brain and heart could
provide a novel mechanism explaining the variable effects of E2 following
menopause. Furthermore, phosphorylated ERβ was detected in the heart and
brain and the consequences of phosphorylation of ERβ on its regulation of
transcription were determined.
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PHOSPHORYLATION OF ERβ AND LIGAND INDEPENDENT ACTIONS
The findings presented in Chapter III add to the renowned complexity
of ERβ signaling. ERβ has been found to function completely differently from
its cognate steroid receptor ERα. ERα binds to DNA and regulates
transcription only in the presence of a ligand, as has been shown by ChIP-seq
experiments in breast cancer cells [216]. Conversely, ERβ can bind to EREs
in absence of ligand, with microarray data showing that ERβ regulates
transcription of three classes of genes [70, 148, 217]. The first and larger
class of genes was regulated by unliganded ERβ. The second class of genes
was regulated only in the presence of ligand, and genes in the smaller third
class were regulated by ERβ both in presence or absence of ligand.
Interestingly, several of the Class I genes in the Vivar et al. study were
enriched for AP-1 sites, demonstrating that unliganded ERβ targets genes
under AP-1 regulation. This is important to consider in light of the results
shown in Chapter III that the ligand independent inhibition of AP-1, which is
characteristic of ERβ, was abolished when either phosphorylation site (S87 or
S105) were mutated. This points to the possibility that the N-terminal domain
is involved in ERβ interaction with a coregulatory protein or directly with
transcription factor Jun/Fos that binds to the AP-1 DNA sequence. Mutation of
either S87 or S105 abolished the ligand independent inhibition of AP-1 sites,
indicating that the genes that Vivar et al. identified as Class I would not be
regulated by phosphorylated ERβ. This could be a potential way of directing
ERβ towards other sets of genes that do not have AP-1 sites in their
promoters. Indeed we found that phosphorylation of ERβ at S105 increased
ERE dependent transcription both in presence or absence of ligand. It is
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possible that when unphosphorylated, ERβ regulates both Class I and
Class II genes but after phosphorylation it is limited to Class II, ERE genes.
As estrogen levels are low after menopause, ERβ is constantly
functioning unliganded causing regulation of only Class I genes. Therefore it
is possible that following menopause, in absence of estrogen, phosphorylation
of ERβ would determine the set of genes it regulates. This modification would
have critical consequences on ERβ signaling at a time when estrogen is low.
PHOSPHORYLATION OF ERβ AND THE DYNAMIC STRUCTURE OF THE
N- TERMINAL DOMAIN
The dynamic structure of ERβ can also be the cause of the profound
consequences of mutations of S87 and S105. The ligand binding domain and
DNA binding domains of ERs have been described via X-ray crystallography
in complex with ligands and ERE sequences respectively [218-224]. However,
the three dimensional structure of the N- terminal domain of ERβ, along with
many other nuclear receptors, has not yet been resolved. Indeed it has been
shown that the AF-1 domains of nuclear receptors possess an intrinsically
disordered (ID) conformation [225, 226]. The lack of particular structures has
been attributed as the cause for the ability of nuclear receptors to interact with
a variety of partners by easily changing structure to adapt and bind to a
partner when the cellular milieu promotes that interaction. Both ERα and ERβ
have an intrinsically disordered nature, however analysis of predicted
secondary structural elements in the ER N-terminal domain shows that ERα
has more α-helix and β-sheet elements than ERβ. The N-terminal domain of
ERα contains 67% random coil conformation, whereas more than 80% of ERβ
is unstructured. The possibility that an unstructured part of a transcription
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factor becomes structured following interaction with a component of the
transcriptional machinery or a coregulatory has been shown for nuclear
receptors such as the glucocorticoid receptor and progesterone receptor [227229]. This is true for ERα as well, which by interacting with TBP (TATA
binding protein) loses its disordered characteristics and becomes folded as
shown by surface plasmon resonance and circular dichroism spectroscopy
[225]. The same study was not able to replicate the experiments performed
with the N-terminal domain of ERα with ERβ. This was attributed to the
impossibility of ERβ to interact with TBP or the need for other proteins that
form the transcriptional complex.
It is also possible that phosphorylation alters the intrinsically
disordered nature of the N- terminal domain and determines the binding
partners of ERβ. Much of what we know about the structure of the N- terminal
domain of ERβ comes from sequence analysis prediction. The “Network
Protein Sequence Analysis” for example, is a web service that was developed
by a biocomputing team from analysis of sequence and structure information
available in large databases [230]. Analysis of the N-terminal domain of ERβ
with a prediction model shows that the biggest majority of it is unstructured
and made of random coil (see Fig. 46) [231]. Strikingly the amino acids close
to S87 form a short α-helix right next to an extended strand region, followed
by a random coil and another short α-helix following S105. Intuitively, it is
plausible to think that even a small change in this sequence at the interface of
unstructured regions and short helices might result in large effects on the
structure of the region. Furthermore, a modification such as phosphorylation
that brings the addition of a negative charge could also result in a
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conformational switch in the area. Changing S87 or S105 into Glutamic
acid (E) would mimic the effect of the phosphate, as experimentally done in
Chapter III, and could help obtain a prediction of the structural conformation of
the N-terminal domain of ERβ following phosphorylation. Indeed when S87
was changed into Glutamic acid, it destabilized the short α-helix close to the
extended strand region and turned it into a random coil. Changing S105 into
S105E had the opposite effect. Even if S105 is further away from the short
helix than S87, S105E induces a conversion of the random coil into a helix
(Fig. 46). This extends the α-helix from 5 to 8 amino acids; a longer α-helix
could limit the dynamic movement of the region and direct ERβ towards
interacting with one binding partner rather than another. As shown in Chapter
III, phosphorylation of ERβ at S105 increased the ligand independent and
ligand dependent activation of ERE dependent transcription which could result
from the stabilization of the α-helix structure and the recruitment of the
transcriptional machinery.
It has been proposed that the unstructured and dynamic status of the
N-terminal domain of ERβ is at the base of its heterogeneous function [210,
226]. Phosphorylation in that region could result in different structural
conformation leading ERβ to interact with a certain binding partner and
therefore towards a specific function.
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Figure 46. Network Protein Sequence Analysis of the N-terminal domain of
ERβ shows the conformational changes potentially induced by
phosphorylation [230].
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PHOSPHORYLATION OF ERβ AND THE INTERACTING PROTEINS
The interactome of ERβ is vast, depending on the tissue under
analysis, and can be altered by hormone treatment in vitro [86, 87]. Indeed
ERβ interacting proteins in the ventral hippocampus were altered by aging
and E2 as shown by a study from our group [86]. It is possible that the
observed changes in ERβ interacting proteins in E2 treated versus vehicle
treated animals might be due to ERβ phosphorylation. As described above,
phosphorylation could deeply alter the structure of the N-terminal domain
which is known to mediate interactions with several proteins such as
coregulators or TATA-binding proteins [128, 225, 232]. Furthermore, as
described in Chapter IV, E2 treatment in the ventral hippocampus inhibits both
ERK and p38 activity. This could cause decreased levels of phosphorylated
ERβ and altered recruitment of interacting proteins, which serves as a
potential explanation for the changes detected in the previous study. Many of
the interactions of ERβ are transient and make determining the effect of
phosphorylation on these interactions difficult. An alternative approach to
determine how phosphorylation of ERβ alters its interactome is using
proteomics techniques such as APEX and BioID [233, 234]. These techniques
are based on biotinylation of proteins proximal to the protein of interest which
is tagged with a biotinylating enzyme. All biotinylated proteins have therefore
interacted with the protein of interest and can be isolated using affinity
chromatography. Mass spectrometry analysis is then used to reveal protein
identity. While this is an in vitro approach to study if phosphorylated ERβ
interacts with different proteins, it would potentially explain some of the

143

observed differences in its function.
MAPKS IN THE AGING FEMALE BRAIN AND HEART
Aging can be defined as “a progressive, generalized impairment of function,
resulting in an increased vulnerability to environmental challenge and a
growing risk of disease and death” [235]. Aging is a continuous process
affecting the whole organism which is changed at all levels, from the
molecular and cellular level to tissue and system levels. In women,
reproductive aging is the decline in fertility that ends at menopause, when
levels of circulating estrogens are low. The decline of circulating estrogens is
accompanied by a decline in health and rise in neurological and
cardiovascular disease [56, 58]. It is plausible to think that the concurrent
aging and estrogen decline together lead to a continuous change in the brain
and heart. Indeed the effects of ET are different depending on how long
following menopause they are administered, indicating that something in the
cellular milieu has changed. It was shown that there is a critical window at
which estrogen can be protective, but the molecular basis for this change is
unknown. It is also not understood whether there is one critical window for all
systems or if estrogens might be beneficial for a larger span of time in one
tissue or another. It was proposed that estrogen action has a “healthy cell
bias”, meaning that if cells are healthy at time of estrogen exposure their
response to estrogen will be beneficial [236]. In contrast, if estrogen is
administered to a cell that is not healthy, estrogen will exacerbate the cellular
stress.
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Context dependent effects of Estrogen
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Figure 47. Context dependent effects of Estrogen.

The results shown in Chapter IV support the idea that the effects of
estrogen treatment depend on the time of administration. Furthermore there is
a clear difference between the results obtained in the heart and in the brain. In
the brain E2 inhibited ERK activity; in the hypothalamus this was true at all
times post OVX, in the hippocampus E2 was only effective 1 week post OVX.
In the heart, however, E2 did not alter ERK or p38 at any time point. This
differential regulation of MAPKs signaling could be indicating that the critical
window of time is different for the brain and the heart, and indeed these two
organs age differently. The brain is very sensitive to aging which is the biggest
risk factor for neurodegenerative disease. The aging brain is characterized by
underlying oxidative stress, neuroinflammation, glial activation, impaired
protein processing and dysfunctional mitochondria [237]. The cardiovascular
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system is also affected by aging which leads to atherosclerosis, thickening
and loss of elasticity of the arterial walls, hypertrophy of the heart, and fibrosis
[238].
A POTENTIAL ROLE FOR PROTEIN PHOSPHATASES
Protein phosphorylation is a reversible and transient mark placed by
kinases and removed by phosphatases. These enzymes are part of a network
that regulates cell signaling pathways and downstream effector proteins. In
the last decade researches have started to focus their studies on the
phosphatases that are responsible in removing the phosphorylation mark
placed by kinases as a potential tool for drug development [239]. Indeed
kinases are the target of several common medications for diseases such as
diabetes, obesity, cancer etc. yet fewer phosphatase modulators are currently
available [239]. Phosphatases can be broadly categorized based on their
substrate recognition as protein Serine/Threonine phosphatases (PSTPs),
Tyrosine phosphatases (PTPs) or dual-specificity phosphatases.
Interestingly, phosphatases have been shown to be differentially expressed
and activated by aging and hormonal status similar to many kinases [240244]. A 2015 study showed that in primates aging significantly inhibited
protein phosphatase 2A (PP2A) and consequently increased α-synuclein
phosphorylation and oligomerization [243]. Similarly, STEP (Striatal-enriched
Tyrosine phosphatase) is less active in the aged rats in several brain regions
[242]. The activity of STEP has also been linked to age-associated neurologic
disorders possibly because it is regulated by oxidative stress. Furthermore,
the hormonal regulation of phosphatases is complex as previously discussed
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for kinases. It was shown that both PSTPs and PTPs can be regulated
by estrogen in healthy and cancer cells [244-248].
The specific phosphatases that target ERβ’s S87 and S105 have not
been investigated, but in vitro experiments could specifically identify which
enzymes are responsible for removing the PTM placed by the MAPKs. It is
plausible that these phosphatases are regulated by age and estrogen similarly
to the results shown in Chapter IV for the MAPKs p38 and ERK. While it was
not a focus of this dissertation, Tyrosine 36 has been recently identified as a
phosphorylation site of ERβ [249]. Using in vitro and in vivo approaches T36
phosphorylation was identified as a switch in determining the antitumor
activity of ERβ in breast cancer. Indeed, phosphorylation of T36 was
necessary for recruitment of coregulatory proteins at promoters of antitumor
genes. Furthermore, the phosphatase EYA2 was shown to remove the
phosphate mark placed by the kinase c-ABL. This is the first example of a
well-defined signaling circuitry that regulates ERβ’s antitumor activity based
on a specific phosphorylation mark.
Identifying the phosphatases responsible for removal of
phosphorylation at S87 and S105 and measuring its changes with age and
estrogen are promising avenues that would complement and strengthen the
data presented in Chapter IV.
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MITOCHONDRIAL DYSFUNCTIONS WITH AGE AND ESTROGEN
EFFECTS
Known targets of estrogen regulation are mitochondria [250-255].
Interestingly mitochondrial dysfunction is common with age, and the
“Mitochondrial theory of aging” proposes that the large amount of reactive
oxygen species (ROS) produced in the mitochondria makes them a prime
target for oxidative damage, which in turns decreases mitochondrial function
and activates signaling pathways such as MAPKs [235, 256]. The three
factors of aging, estrogen signaling and mitochondria are clearly intertwined
and likely play an important role in the insurgence of the neurological and
cardiovascular diseases associated with aging in women.
Estrogen can regulate mitochondrial function both in a genomic way,
by regulating transcription of mitochondrial proteins, and in a non-genomic
way by regulating signaling pathways such as MAPKs that converge on
mitochondria. Interestingly, two studies have looked at the mitochondrial
proteome of the heart or the brain following estrogen treatment or estrogen
deprivation via ovariectomy [257, 258]. The majority of the proteins that were
altered by estrogen were involved with regulation of oxidative stress,
apoptosis, and electron transport complex proteins. Furthermore, the
respiratory rate and activity of respiratory chain enzymes were increased in
brain mitochondria 24 hours following E2 treatment, indicating the possibility
for either a genomic regulation of transcription of genes in those functions or a
non-genomic activation of signaling pathways that led to regulation of
mitochondrial respiration [259].
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Many of the beneficial effects of estrogen on mitochondria are thought
to be due to ER dependent transcription of NRF-1, nuclear respiratory factor-1
[260]. NRF-1 is a transcription factor that regulates transcription of
mitochondrial genes in the nuclear DNA. Interestingly, the NRF-1 promoter
has ERE and AP-1 sites in its promoter and both ERα and ERβ can induce its
transcription [260, 261]. In breast cancer cells, it was found that unliganded
ERβ represses the NRF-1 promoter via the AP-1 site, but E2 or Tamoxifen
treatment relieves this repression [261]. An in vivo study E2 treatment in
ovariectomized rats determined an increase in NRF-1 and several
mitochondrial protein levels and enzymatic activity in mitochondria isolated
from cerebral blood vessels [262]. The authors conclude that vasoprotection
by estrogen treatment might be due to the measured improved mitochondrial
function, improved respiration and reduced production of ROS.
The non genomic effects of estrogens on mitochondria often include
MAPKs signaling regulation. In in vitro experiments of human lens epithelial
cells, E2 treatment reduced ROS produced by the mitochondria by activating
ERK signaling which in turn stabilized the mitochondrial membrane potential
[263]. Similarly, in cultured hippocampal neurons, brief E2 treatment reduced
toxicity of elevated Glutamate which usually results in elevated Ca 2+ [264].
Instead, brief E2 treatment increases the storage of Ca2+ in mitochondria and
an elevation of the antiapoptotic gene Bcl2 [264]. In an in vitro model of AD,
treatment with E2 inhibited the amyloid induced translocation of the
proapoptotic protein Bax to the mitochondria and increased the antiapoptotic
Bcl2 levels [265].
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This estrogen regulation of mitochondrial function via MAPKs has been
identified in vivo as well. Exercise-induced myocardial hypertrophy is a
physiological response to exercise that does not lead to fibrosis and is
reversible. Interestingly females develop larger physiological hypertrophy
which is proposed to contribute to the more favorable remodeling in response
to pathological stimuli seen in females [266]. It was shown that exercise in
females induces activation of ERK and p38 which phosphorylate transcription
factors that activate expression of mitochondrial proteins, leading to increased
mitochondrial mass to better cope with the increased size of myocytes. This
process was not present in ERβ knockout mice, indicating that ERβ is
necessary for the activation of MAPKs and improved response to exercise
[266].
As shown above, often the non-genomic effects of estrogen on
mitochondrial function require activation of MAPKs which does not correlate
with the results from our deprivation paradigm. In the hypothalamus, for
example, E2 treatment strongly inhibited ERK at all time points. Does that
mean that mitochondrial function is repressed in these samples? It is difficult
to predict, because of the complexity of ERK signaling. However, if
mitochondrial function was indeed reduced this could mean that the window
for estrogen’s protective effects is closed in the hypothalamus. Interestingly in
this brain region, longer deprivation caused stronger inhibition of ERK,
possibly leading to an even worse phenotype. This could be an example of
the “healthy cell bias”: longer deprivation from estrogen and aging could lead
to unhealthier cells which more drastically respond to E2 treatment. In the
heart both ERK and p38 were decreased by prolonged estrogen deprivation
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and E2 treatment did not rescue this phenotype. This could again determine a
failed protective response by E2, potentially due to altered cellular milieu.
Because many of the protective effects of estrogen on mitochondrial functions
are mediated by genomic regulation, it would be important to determine
whether the NRF-1 transcription factor or the mitochondrial proteins known to
be transcribed following estrogen treatment are increased in the E2 treated
animals.
In conclusion, the role of mitochondria in the beneficial effects of
estrogens is known and could be a mechanism by which aging and estrogen
together lead to time dependent effects.
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FUTURE DIRECTIONS
The studies presented here contribute to the understanding of estrogen
receptor signaling and kinase regulation in the context of menopause.
Importantly, these data support the ideas that post translational modifications
alter ERβ’s functions and that the length of estrogen deprivation alone can
affect the intracellular milieu of the aged brain and heart.
There are many new possible lines of investigation brought about from
these findings. First, the in vitro evaluation of the effects of ERβ
phosphorylation on its activity as a transcription factor was a necessary
starting point. While the abolished ligand independent activity of ERβ by
mutation of either phosphorylation site was striking, the data presented do not
provide an explanation for this change. The idea proposed above, that
phosphorylation alters ERβ’s network of interactions, is compelling also due to
the dynamic structure of ERβ near its phosphorylation sites. Using an in vitro
approach such as BioID or APEX, the consequences of ERβ phosphorylation
on its interaction with other proteins could be investigated [233, 234].
Furthermore the phosphorylation status of ERβ in vivo needs to be
determined. The proteomics approach described in Chapter V will
conclusively determine how phosphorylation of ERβ changes in vivo. This is
crucial because of the results of Chapter III; namely ERβ’s regulation of
transcription is altered by phosphorylation. Furthermore, in light of the results
of Chapter IV, it is likely that phosphorylation of ERβ will be decreased in the
brain and heart following E2 treatment, because ERK and p38 kinase were
overall depressed.
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The other potential for investigation that is opened by these studies is
the possibility that the altered MAPKs signaling after prolonged estrogen
deprivation might result in mitochondrial dysfunctions. Indeed, I would
hypothesize that following prolonged estrogen deprivation mitochondrial
function in the brain and the heart would be reduced. Measuring mitochondrial
function in the deprivation paradigm used here could be a meaningful
assessment of cellular health. Furthermore, in vitro studies have shown that
activation of MAPKs signaling is necessary for estrogen’s positive effects on
mitochondrial function. According to the data shown in Chapter IV, however,
ERK and p38 were in general not activated by E2, suggesting that either
MAPKs signaling is differentially regulated in vivo or potentially that the
window of opportunity is closed in these tissues. Finally, the beneficial effects
of E2 on mitochondrial function can be determined by increased NRF-1 levels
which could be measured in the brain and heart in our deprivation paradigm. If
the beneficial effects of E2 are mediated via the genomic pathway, NRF-1 will
be increased, resulting in higher levels of mitochondrial proteins necessary for
efficient mitochondrial respiration.
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CHAPTER VIII
BROAD CLINICAL IMPLICATIONS
CLINICAL POTENTIAL OF ERΒ
The Timing Hypothesis that resulted from the Women’s Health Initiative
study is at the base of this dissertation work. Because of the age dependent
effects of estrogen treatment in post-menopausal women physicians are often
uncertain on whether it is a good option for their patients. Furthermore, the
activation of ERα in the uterus or breast with estrogen treatment could lead to
proliferation and cancer. This is often a concern of physicians and patients
who decide to avoid ET. Therefore, ERβ selective agonists have been
evaluated in the past 10 years, because ERβ does not induce reproductive
tissue proliferation and is active in non-reproductive organs such as the brain
and heart. For its neuroprotective and cardioprotective roles, ERβ is a
potential target of regulation for age and menopause related diseases.

ERβ specific ligands in post menopausal
women
Promote

Avoid

Neuroprotection

Breast/uterine
proliferation

Cardioprotection

Figure 48. Potentials for ERβ specific treatment in post-menopausal women
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NEED FOR BETTER UNDERSTANDING OF ERΒ SIGNALING
A potential pitfall of using ERβ specific ligands in the clinic is that many
aspects of ERβ signaling are still unknown. The characteristic ligand
independent activity of ERβ in activating ERE dependent transcription and
inhibiting AP-1 dependent transcription remains mostly unexplained. Indeed
ERβ can interact with coregulatory proteins or transcription factors, bind to
DNA and regulate transcription in absence of ligand. Furthermore while
classically steroid receptors only translocate to the nucleus following ligand
binding, ERβ can be found in the nucleus or other subcellular locations in
absence of ligand. It is thought that the ligand independent functions of ERβ
are particularly important after menopause when estrogens are low. Taking
advantage of the functional and structural differences between ERα and ERβ
several receptor specific ligands (SERMs) have been developed. ERβ specific
botanical compounds known as phytoestrogens had been used for centuries
in Chinese medicine. Different formulations of phytoestrogens have been
tested in preclinical and clinical studies and have been deemed viable options
for postmenopausal symptoms such as hot flashes, decreased memory
function and menopause associated neurological decline [267-270]. Several
phytoestrogens can bind to both ER isoforms, but selectively act on ERβ to
induce recruitment of coregulatory proteins and activate transcription [271].
This selectivity ensures that ERα in reproductive tissues such as the breast
and uterus is not activated and does not lead to proliferation and possibly
cancer [271]. An approach used to limit ERα activation in postmenopausal
women with breast cancer is to use Aromatase inhibitors [272]. Inhibition of
aromatase leads to decreased circulating estrogens and reduced ERα
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activation. Because ERβ can act in absence of ligand, use of Aromatase
inhibitors could reduce endogenous estrogens thereby highlighting ligand
independent actions of ERβ. More agreement on the beneficial effects of
ERβ’s activation post menopause is leading to development of
pharmaceuticals that take advantage of the growing understanding of ERβ’s
to improve post-menopausal women’s life.
Clinical and basic science studies have evaluated the use of SERMs
on ERβ; however it is possible that following phosphorylation of ERβ
treatment with SERMs does not lead to the same effects. Indeed in Chapter III
I show that phosphorylation of ERβ alters its E2 dependent and independent
regulation of transcription in neurons. It is a possibility that treatment with
other ligands could have alternate effects. The results in Chapter IV show that
MAPKs are differentially activated following estrogen deprivation and E2
treatment which could correlate with altered levels of ERβ phosphorylation in
vivo. While it is difficult to speculate on the physiological consequences of
altered levels of phosphorylated ERβ in the brain and heart, in vitro studies
point out that a big effects would be the abolished ligand independent
inhibition of AP-1 dependent transcription. This would result in increased
transcription of the genes that are usually repressed by ERβ in absence of
ligand when ERβ phosphorylation is high. The other important effect of ERβ
phosphorylation was the increased activation of ERE dependent transcription.
Taken together, increased phosphorylation of ERβ in vivo due to increased
MAPKs activity would lead to a shift in its action from the inhibition of AP-1 to
the activation of ERE.
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A further complicating factor is that while only ERβ1 transcriptional
regulation was tested in Chapter III, several splice variants exist. Interestingly
all splice variants still include the N-terminal domain, therefore could be
phosphorylated as ERβ1 is. Furthermore the human ERβ splice variants are
truncated in the C-terminal domain, therefore lack the ligand binding domain.
These ERβ splice variants can regulate transcription in absence of ligand,
indicating that the N-terminal domain is necessary for its constitutive activity
[70]. A recent study by our group detected ERβ2 splice variant, which has an
insertion of 18 amino acids in the ligand binding domain, in the brain regions
analyzed in Chapter IV [273]. Therefore it is possible that both ERβ1 and
ERβ2 are differentially phosphorylated correlating with the altered MAPKs
activation measured. Indeed more understanding on the dynamics of ERβ
splicing and phosphorylation in the context of aging and estrogen deprivation
might uncover a potential target for regulation. Drugs targeting splicing and
phosphorylation are available, therefore understanding which splice variant
and phosphorylation status are optimal for ERβ to have most benefits would
be highly important for physicians.
CLOSING REMARKS
My findings shed light on the molecular characteristics of
phosphorylated ERβ as well as highlighting the potential contribution of
MAPKs signaling in the brain and heart in response to estrogen deprivation
and E2. As predicted, I found that the cellular milieu of the aged brain and
heart is altered by prolonged estrogen deprivation. While MAPKs signaling
could affect brain and heart physiology through many critical cellular
pathways, we found that when phosphorylated ERβ differentially activates
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transcription. Therefore, if indeed MAPKs and consequently ERβ are
differentially modulated by age and estrogen deprivation this could provide a
molecular basis for altered response to ET. These findings highlight the need
for further investigations on the effects of prolonged estrogen deprivation in
post-menopausal women and provide a molecular explanation for the Timing
Hypothesis.
While the understanding of the molecular underpinnings of the Timing
Hypothesis is still unclear, the clinical evidence that points toward the benefits
of ET in post-menopausal women is strong. Studies enrolling large numbers
of women and with the appropriate experimental design show that ET is
neuroprotective and cardioprotective following menopause. Furthermore,
recent studies evaluating ERβ selective agonists are very encouraging and
could remove the disadvantage of activating ERα in reproductive tissues. The
societal and economical burden of post-menopausal issues ranging from hot
flashes to dementia or atherosclerosis should serve as an incentive for
doctors to prescribe ET to women, but at the right time (i.e. in
perimenopause). In conclusion, I would recommend the use of ET to
perimenopausal women, and I predict that soon ERβ specific agonists will
have strong evidence in support of their use in the clinic.
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CHAPTER VIII
GENERAL METHODS
Ethics Statement
Animal procedures were designed to minimize pain and suffering. All
animal protocols were approved by the Institutional Animal Care and Use
Committee (IACUC) at Loyola University Chicago, permit number 2009018.
Animals and deprivation paradigm
Female Fischer 344 rats were obtained from the National Institute of
Aging (NIA) colony (Taconic) at 18 months (N = 80) of age. The animals were
allowed to acclimate to the housing facility for 7 days after arrival. Animals
were housed two per cage and were allowed free access to standard rat chow
and tap water. One week after arrival, animals were deeply anesthetized with
vaporized isoflurane and bilaterally ovariectomized (OVX). Briefly, the ovary
and distal end of the uterine horn were pulled from the body cavity through a 1
cm incision made through the skin and body wall. The uterine horn was
clamped with a hemostat and ligated proximal to the clamp. The entire ovary
and distal uterine horn were then removed. Animals were singly housed and
provided with acetaminophen analgesic (122.7 mg/kg) in their water for 3
days postoperative.

During this time, animals were weighed once/day and their water intake
was measured. Following 3 days of analgesia the animals were pair-housed
with their previous cage mate for the duration of the experiment. Following
OVX animals recovered for 1, 4, 8, or 12 weeks (N=20/age group, Fig. 7).
After the designated recovery time the animals were given a subcutaneous
injection of either safflower oil (vehicle) (N=10/age group) or 2.5 μg/kg 17βestradiol (E2, N=10/age group) dissolved in safflower oil once/day for 3 days.
This dose of E2 elevated levels in OVX female rats (56.5 ± 6.3 pg/ml, which is
within physiological range of women who received hormone replacement
therapy during post-menopause (17-75 pg/ml)[178]. Animals were euthanized
24 hours after the last injection, trunk blood was collected, brain and heart
rapidly removed and flash frozen.
Tissue Collection
The hypothalamus, dorsal and ventral hippocampus were microdissected
using a Palkovit’s brain punch tool (Stoelting, Inc., Wood Dale, IL) according
to “The Rat Brain in Stereotaxic coordinates” [274]. The left ventricle was also
rapidly removed from heart that had been flash frozen and homogenized
using silica beads and a Mini Beadbeater-8 (Biospec Products, Bartlesville
OK).
CHAPTER III METHODS
PhosTagTM Electrophoresis
50 ug of dorsal hippocampus or heart (left ventricle) protein was run on
precast PhosTagTM Acrylamide 12.5% Acrylamide gels, (Wako Pure
Chemical Industries, Osaka, Japan). The gel was then transferred on a PVDF
membrane (Promega, Madison WI), blocked for 1 hour with 5% BSA, then
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incubated with the Estrogen receptor β antibody H150 (epitope: 1-150
fragment of hERβ, N-terminal domain) (Santa Cruz, sc-8974, Dallas TX) at a
1:250 dilution in 5% BSA TBST overnight. Blots were washed twice with
TBST for 10 minutes prior to application of 1:5000 goat α-rabbit-HRP (Santa
Cruz, sc-2004, Dallas TX) in 5% BSA TBST. Blots were washed twice with
TBST for 10 minutes and imaged on the Bio-rad Chemidoc XRS+ imager
(Bio-rad, Hercules, CA) using ECL Chemiluminescent substrate (Pierce
Scientific, Rockford IL). Densitometry was performed using ImageLab
software. Antibody specificity was confirmed with parallel Western Blots and
PhosTagTM blots using ERα H-184 antibody (Santa Cruz, sc-7207, 1:1000
dilution; data not shown).
Alkaline Phosphatase treatment
Specificity of phosphorylated proteins were confirmed by treating 50 µg of
dorsal hippocampus protein (vehicle-treated animals) with 0, 30 or 60 units of
alkaline phosphatase (Roche, Basel, Switzerland) for 2 hours at 37°C to
dephosphorylate all phosphorylated proteins.
Cell culture
The mouse hippocampal-derived cell line HT-22 (generously provided by Dr.
David Schubert, Scripps Institute, San Diego, CA) was maintained in DMEM
(Corning, Tewksbury, MA) containing 4.5% glucose and L-glutamine
supplemented with 1x nonessential amino acids (Corning, Tewksbury, MA)
and 10% fetal bovine serum (FBS) (Atlanta Biologicals, Norcross, GA). Cells
were used at 70-80% confluency for all experiments.
Hormone treatments
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Cells at 70-80% confluency were rinsed with 1x PBS and then media replaced
with phenol red-free DMEM plus 10% charcoal-stripped FBS (Atlanta
Biologicals, Norcross, GA) at least 36 hours prior to hormone treatments in
order to remove all exogenous hormone sources. 17β-estradiol (Sigma, St.
Louis, MO) and 4-OH Tamoxifen (Sigma, St. Louis, MO) were diluted in
molecular grade ethanol (EtOH) (Sigma, St. Louis, MO) and used at a final
concentration of 100 nM as described previously [70, 136].
Expression vectors and reporter constructs
Plasmid expression vector (pcDNA 3.0; Invitrogen, Carlsbad, CA) containing
inserts for rER-β1 was provided by Dr. Tom Brown (Pfizer Corp., Cambridge,
MA) and has been extensively characterized [8]. The ERE-tk-luciferase
reporter construct (generously donated by Dr. Paul Budworth, Case Western
Reserve University, Cleveland, OH) contains two repeats of the consensus
vitellogenin ERE sequence upstream of the minimal thymidine kinase
promoter-firefly luciferase (2xERE-tk-luc) in pGL2-basic plasmid (Promega,
Madison, WI). The AP-1-tk-luciferase reporter construct (generously provided
by Dr. Colin Clay, Colorado State University, Fort Collins, CO) contains three
repeats of the AP-1 sequence into pGL2-basic plasmid. The renilla luciferase
pGL4 reporter construct (Promega, Madison, WI) was used as an internal
control for transfection efficiency.
Site directed mutagenesis
The pcDNA3.0 plasmid expression vector (Invitrogen, Carlsbad, CA)
containing a cDNA insert coding rat ERβ1 was mutated using the Quick
Change II XL site-directed mutagenesis kit (Agilent, Santa Clara, CA) to
create the phospho-mutants (see Table 1). Primers were designed using the
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QuickChange primer design available from the Agilent website and point
mutations were inserted following manufacturer’s instructions. Vectors were
validated by DNA sequencing (ACGT, Inc, Wheeling, IL) to confirm successful
site directed mutagenesis.
Transient Transfections
HT-22 cells were plated at a density of 20000 cells /well in 96-well plates for
48 h before transfection. Transfections were carried out using Fugene6
(Roche, Basel, Switzerland) or Fugene9 (Roche, Basel, Switzerland)
according to manufacturer’s instructions. Twenty-four hours after transfection,
cells were washed with 1x PBS and incubated with dextran charcoal-stripped
media containing hormone treatment or vehicle (EtOH) for 15 h and then
lysed for luciferase assays. Transfection efficiency and expression was
verified prior to luciferase experiments using GFP-tagged constructs (data not
shown).
Luciferase assays
Following lysis, control reporter (Renilla Luciferase) and reporter (Firefly
Luciferase) activities were measured using the Dual-Luciferase Reporter
Assay system (DLR; Promega, Madison, WI). Relative light units (RLU) were
detected using a Biotek Synergy HT plate reader (Biotek, Winooski, VT) with
automatic dual injector system and represented as a ratio of Firefly/Renilla
Luciferase RLU. All experiments were conducted with 6 replicates for each
condition in each 96 well plate and each assay was repeated in 4 or more
independent experiments.
Statistics
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Two way ANOVA was performed to determine statistical significance and
interaction between the groups followed by Tukey post hoc test for
comparisons between mutants and wild type vector. Significance was set at P
value < 0.05. All transfection data are represented as the mean percent
change in fLUC/rLUC compared to vehicle-treated cells transfected with
empty vector ± SEM.

CHAPTER IV METHODS
RNA Isolation
Trizol reagent (Invitrogen, Carlsbad CA) was used to isolate total RNA from
the hypothalamus, ventral hippocampus, dorsal hippocampus, and left
ventricle of the heart. All RNA samples were quantified using Nanodrop
spectrophotometry and analyzed for quality by visualization of the RNA on
1.5% agarose gel.
Quantitative reverse transcription PCR (RT-qPCR)
Following RNA isolation, 1.0 µg total RNA was reverse transcribed using the
SuperMix VILO cDNA synthesis kit for RT-qPCR (Invitrogen, Carlsbad, CA).
Roche FastStart SYBR Green Master Mix was added to intron-spanning ERK
and p38 primers: ERK forward: 5’CTCGGATTCCGCCATGAGAA3’, reverse:
5’GGTCGCAGGTGGTGTTGATA3’; p38 forward:
5’CAGGAAACGGGACGAACAGA3’, reverse:
5’CCACAGAACTGCATGTCCCT3’. Then, 2 µL cDNA templates were added
to duplicate reactions performed in 96 well plates. The following program was
used for RT-qPCR: 1) 95°C for 10 minutes, 2) 95°C for 30 seconds, 3) 59°C
for 30 seconds, 4) 72°C for 30 seconds, and melting curve analysis. All
samples were normalized to the hypoxanthine guanine phosphoribosyl
transferase 1 (HPRT) housekeeping gene (primers: forward:
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5’AGCAGTACAGCCCCAAAATGG3’, reverse:
5’TGCGCTCATCTTAGGCTTTGT3’), as it is not altered by E2 treatment [178,
179]. Quantification of the target gene expression was achieved using the
∆∆CT method [275].
Protein Isolation
Total protein was extracted from the hypothalamus, dorsal hippocampus and
ventral hippocampus using T-Per reagent (ThermoFisher Scientific, Waltham
MA) supplemented with Pierce Protease and Phosphatase Inhibitor Tablet,
EDTA Free (ThermoFisher Scientific, Waltham MA). Similarly, total protein
was extracted from the left ventricle of the heart using RIPA buffer
supplemented with Pierce Protease and Phosphatase Inhibitor Tablet, EDTA
Free (ThermoFisher Scientific, Waltham MA). Protein concentrations were
measured using the Pierce BCA Protein Assay kit according to manufacturer’s
directions (ThermoFisher Scientific, Waltham MA).
Western Blot
10 μg of isolated protein was electrophoresed on a 10% acrylamide gel. The
gel was then transferred on a PVDF membrane (Promega, Madison WI),
blocked for 1 hour with 5% Bovine Serum Albumin (BSA, ThermoFisher
Scientific, Waltham MA) in Tris Buffered Saline with 0.1% Tween (TBST),
then incubated with primary antibodies in 5% BSA TBST overnight (Table 4 –
detailed antibody information). Blots were washed twice with TBST for 10
minutes prior to application of a secondary antibody in 5% BSA TBST for 2
hours, then blots were washed twice with TBST for 10 minutes and imaged
using a Bio-rad Chemidoc XRS+ imager following application of the Pierce
Enhanced Chemiluminescence (ECL) Western Blot substrate (ThermoFisher
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Scientific, Waltham MA). PonceauS staining (MP Biomedicals,Santa Ana CA)
was used to detect total protein. Quantification of bands was achieved by
measuring the intensity of the bands following normalization to total protein
with ImageLab software. Biological replicates were 6-8 per treatment/time
point and samples were repeated in 2-3 technical replicates.

Table 4. Details of antibodies used in Chapter V
Peptide/Protein target

Name of Antibody

Total ERK1/2

ERK1 antibody (K-23)

Total p38α, p38β, p38γ

p38 MAPK (D13E1)

PhosphoERK1/2
Phosphop38α, p38β,
p38γ
Rabbit IgG

Phospho-p44/42 MAPK
(Erk1/2)
(Thr202/Tyr204)
Phospho-p38 MAPK
(Thr180/Tyr182)
Anti-rabbit IgG, HRPlinked

Catalog #, ,manufacturer
sc-94, Santa Cruz, Dallas TX
8690S, Cell Signalling Techinology ,
Danvers MA
9101s, Cell Signalling Techinology ,
Danvers MA
4511s, Cell Signalling Techinology ,
Danvers MA
7074s, Cell Signalling Techinology ,
Danvers MA
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Species raised in; mococlonocal or Dilution
polyclonal
Used
Rabbit, polyclonal
1:500
Rabbit, monoclonal

1:500

Rabbit, polyclonal

1:500

Rabbit, monoclonal

1:500

Goat, polyclonal

1:5000

CHAPTER V METHODS
Expression vectors and reporter constructs
Rat ERβ sequence was cloned in the plasmid expression vector pEXPCT/TOPO (Invitrogen, Carlsbad, CA) using EcoRI (NEB, Ipswich, MA)
restriction enzyme digestion. The insertion was verified by sequencing which
confirmed that 6His were inserted after the last amino acid of ERβ.
Recombinant His-Tagged Protein Expression and Purification
BL21 DE3 (generously donated by the Lab of Dr. de Tombe) competent cells
were transformed with ERβ-6His plasmid DNA, and grown on LB-Amp plate
overnight. Five colonies were picked for screening and grown in duplicates
until culture turbidity reached OD600=0.4. Then IPTG was added to one
duplicate (B, induced cells) of each colony to induce expression of ERβ-His6
under control of the Lac promoter. After additional incubation at 37°C for 5
hours, cells were centrifuged and resuspended in Lysis Buffer. After
sonication (10” pulses/4 times), supernatant was resuspended in Laemmli
buffer, heated for 5” at 95°C and electrophoresed on a 4-15% acrylamide gel
(Bio-rad, Hercules, CA). The gel was then stained with 1% Coomassie R250, 10% Acetic Acid, 40% Methanol solution for 30’, destained for30” and
imaged with Bio-rad Chemidoc XRS+ imager (Bio-rad, Hercules, CA). Based
on the result, the highest expressing colture was inoculated in 10 ml of LBAmp. After overnight growth the large scale protein production started by
inoculating 8 ml of the colture in 2 L of LB-Amp. The colture was then induced
with IPTG and incubated at 37 °C. Cell pellet was then sonicated (30”
pulses/4 times) and centrifuged at 10000rpm, 20’, 4°C. Supernatant was used
for protein purification performed by Menjie Zhang (Dr. de Tombe lab) with an
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automated FPLC system (AKTÄ FPLC, GE Healthcare). The sample was
loaded on a HisTrap nickel affinity column (GE Healthcare). The column was
then washed until ultraviolet absorbance at 280 nm reached equilibrium. ERβHis6 was then eluted using a buffer containing imidazole (which competes for
binding the column) and the flow through was collected in separate fractions.
Fractions were then electrophoresed and stained with Coomassie R-250 to
verify which fractions contained ERβ-His6. The positive fractions were
combined and concentrated using Pierce Protein Concentrator tubes (Pierce
Scientific, Rockford IL). Protein concentration was measured using the Pierce
BCA Protein Assay kit according to manufacturer’s directions (ThermoFisher
Scientific, Waltham MA). To verify correct expression, ERβ-His6 protein was
then electrophoresed on an Acrylamide 4-15% gels (Bio-rad, Hercules, CA).
The gel was then transferred on a PVDF membrane (Promega, Madison WI),
blocked for 1 hour with 5% BSA, then incubated with the Estrogen receptor β
antibody H150 (epitope: 1-150 fragment of hERβ, N-terminal domain) (Santa
Cruz, sc-8974, Dallas TX) at a 1:500 dilution in 5% BSA TBST overnight. Blot
was washed twice with TBST for 10 minutes prior to application of 1:5000
goat α-rabbit-HRP (Santa Cruz, sc-2004, Dallas TX) in 5% BSA TBST. Blot
was washed twice with TBST for 10 minutes and imaged on the Bio-rad
Chemidoc XRS+ imager (Bio-rad, Hercules, CA) using ECL
Chemiluminescent substrate (Pierce Scientific, Rockford IL). After
confirmation of ERβ-His6 expression, recombinant His- tagged protein was
aliquoted and stored at -80 °C.
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Tryptic digestion and MALDI-TOF analysis
5 to 20 ug of Erbeta-His6 protein was electrophoresed on a 4-15% Acrylamide
gel (Bio-rad, Hercules, CA). The gel was then stained with Coomassie G250
(1% Coomassie G-250, 10% acetic acid, 40% Methanol) for 1 hour and
destained overnight. The band corresponding to the ERβ-His6 protein was
excised using a sterile scalpel; a negative control band with no protein was
also excised. Gel bands were individually put in a 1.5 ml tube and washed
with 50% Acetonitrile 50 % 100mM Ammonium Bicarbonate for 15’ at 37°C
while shaking at 800 rpm. Then the “wash cycle” was performed. First bands
were washed with a 100% 100mM Ammonium Bicarbonate for 15’ at 37°C
while shaking at 800 rpm. Then they were washed with a 50% Acetonitrile
50% 100mM Ammonium Bicarbonate solution for 15’ at 37°C while shaking at
800 rpm. Then they were washed with 100% Acetonitrile for 15’ at 37°C while
shaking at 800 rpm. The gel bands were reduced using 10 mM DTT for 30’ at
37°C while shaking at 550 rpm. The “wash cycle” was then repeated. Then
gel bands were alkylated with 55mM Iodacetamide in 100 mM Ammonium
Bicarbonate solution for 45’ at 37°C while shaking at 550 rpm. The “wash
cycle” was then repeated. The gel bands were then treated with 1 ug of
Trypsin on ice 1 hour, then overnight at 37°C while shaking at 550 rpm. The
supernatant containing most digested peptides was saved. The gel bands
were then washed according to the “wash cycle” to collect all possible
remaining peptides from the gel. The washes were collected and pooled.
Peptides were concentrated using a Speedvac. Peptides were then
resuspeded in 0.1% Formic Acid.
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The standard curve calibrants for MALDI-TOF and the peptides were then
mixed with the α-Cyano-4-hydroxycinnamic acid matrix (CHCA) matrix
(ThermoFisher Scientific, Waltham MA). The Axima-CFR Plus MALDI-TOF in
reflecton mode was calibrated using a mix of the calibrants spotted on the
target plate. Calibrants mix solution was pipetted next to each sample and
calibration was repeated between each measurement.
LC-MRM development
A Thermo Scientific TSQ Vantage MS system was used for these
experiments. The target peptides (SPWCEAR) were synthetized by
ThermoFisher Scientific (Waltham MA) and used for the development of the
MRM method. Peptides were resuspended in 50% Acetonitrile 0.1% Formic
Acid to a 10picomle/ul concentration, aliquoted and stored at -80 °C. Peptides
were diluted at 1picomol/ul and full scan was collected after direct injection of
5ul. Parent ions were then detected and identified. The 2+ parent ion was
then selected for fragmentation and a full MS/MS scan was collected. Four
transitions (precursor-product ions combinations) were picked for each
peptide to be used for the MRM method. The MRM method was prepared
using the Xcalibur software (ThermoFisher Scientific, Waltham MA). Peptides
were combined in equal amounts and injected through in a Biobasic C18
HPLC column (ThermoFisher Scientific, Waltham MA) in a 66 minutes long
LC-MRM method. The MS/MS spectra collected were analyzed using the
Skyline software, created by the MacCoss lab at the University of
Washington.
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